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In comparison with other tissues, bone has a robust healing capacity. However, large 
bone defects regenerate only to a limited extent, and it remains a substantial 
therapeutic challenge to deal with this issue (Zhang et al. 2012). Critical bone defects 
observed in a variety of conditions, e.g. acute injuries, major fractures, hip implant 
revision, fall fractures in osteoporotic patients, and tumours all require resection of 
the affected bone. After removal of the bone, autograft or allograft bone tissue and 
prosthetic implants are commonly implanted. However, these methods have several 
limitations, including patient pain, the risk of an immune reaction, disease 
transmission, and a non-optimal interaction between the body and the implanted 
materials (Pearce et al. 2007; Tu et al. 2009). Bone tissue engineering is a promising 
novel discipline dealing with ways to bridge a bone defect with healing procedures 
that are stable and durable, and that do not introduce any new problems or 
complications (Bose et al. 2012; Hutmacher 2000). 
 
1.1. Bone composition 
Bone is a composite material consisting of collagen (17–20 wt.%) stiffened by an 
extremely dense filling and surrounded by calcium phosphate Ca10(PO4)6(OH)2 
crystals of hydroxyapatite (HA) (69–80 wt%), and other components, notably water, 
proteins and polysaccharides, living cells and blood vessels (Currey 2012; Ferreira et 
al. 2012; Marks and Odgren 2002). HA crystals are precipitated on the surface of the 
nanofibrils of type I collagen (Currey 2012). Apatite compounds in natural bone are 
needle-like or rod-like in shape, 40–60 nm in length, 10–20 nm in width, and 1–3 nm 
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in thickness (Abdal-hay et al. 2013). The outer surface of the bone is organized into a 
dense fibrous layer called the periosteum. The inner surface of the bone, including 
the inner surface of the trabeculae of cancellous bone, is lined with a delicate layer 
called endosteum. Cells of a different type are found in periosteum and in 
endosteum. All of them play an important role in the formation of bone tissue. The 
main types of cells include osteoblasts, osteocytes and osteoclasts. Osteoblasts are 
derived from osteoprogenitor cells. These cells are originated from mesenchymal 
stem cells (MSCs). Osteoblasts secrete type I collagen and some non-collagenous 
proteins, such as osteocalcin (OC), bone sialoprotein and osteopontin. Osteoblasts 
also promote the process of mineralization, which is thought to be initiated by the 
matrix vesicles that build from the plasma membrane of osteoblasts to create an 
environment for the concentration of calcium and phosphate, allowing crystallization 
(Höhling et al. 1978). Collagen serves as a template, and may also initiate and 
propagate mineralization independent of the matrix vesicles (Mackie 2003). 
Osteocytes are cells of fully-formed bone. Osteocytes originate from osteoblasts, and 
are located in small chambers called lacunae, which consist of products secreted by 
osteoblasts. Cytoplasmic processes of communication between osteocytes take 
place via small channels called canaliculi. Nutrients and waste products are 
exchanged through these channels. Osteocytes are also involved in bone 
remodeling, which is influenced by muscle activity. Osteocytes provide alerts to 
increase muscle activity by signaling to other osteocytes, and start the whole process 
of transforming the bone tissue in response to the load. For example, bone becomes 
compacted and stronger with frequent physical exertion or exercise, and becomes 
weaker with inactivity or a low level of physical activity. 
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Osteoclasts are large branched bone cells which are capable of movement. 
Osteoclasts are multinucleated cells, mostly with up to 50 nuclei. Their origin is still 
not completely clear. Scientists initially thought that osteoclasts have the same origin 
as other bone cells, but recent studies have suggested that they originate from 
monocytes, apparently by merging several of these cells. The main function of 
osteoclasts is to degrade the bone mass using various collagenases and other 
enzymes that produce hydrogen ions and cause degradation of calcium crystals. The 
activity of osteoclasts is tightly regulated by various cytokines and hormones, and 
also by parathyroid hormone and calcitonin (Young et al. 2013). 
1.1.1. Two forms of bone that can be found in the human body 
Woven bone – this is an immature form with randomly arranged collagen fibers in 
the osteoid. Woven bone is formed when osteoblasts produce osteoid rapidly, as in 
fetal development, and in adult bone when pathologically rapid formation of new 
bone occurs, e.g. in fracture healing. The rapidly formed woven bone is eventually 
remodeled to form lamellar bone, which is physically stronger and more resilient. 
Virtually all bones in a healthy adult  are lamellar.  
Lamellar bone – this is composed of regular parallel bands of collagen arranged in 
sheets.  
Two forms of lamellar bone are known: 
Compact bone – this is composed of parallel bony columns which, in long bones, are 
disposed parallel to the long axis, i.e. in the line of stress exerted on the bone. Each 
column is formed from concentric bony layers or lamellae arranged around a central 
channel containing blood vessels, lymphatics and nerves. These neurovascular 
channels are known as Haversian canals, and together with their concentric lamellae 
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they form Haversian systems. Neurovascular bundles interconnect between 
themselves and also with the endosteum and periosteum through Volmann channels, 
which pierce the columns at right angles to the Haversian canals. Every Haversian 
system (osteon) develops by osteoclasts tunneling solid bone mass to form a broad 
channel in which blood vessels and nerves grow. It subsequently becomes internally 
lined with active osteoblasts, which provide a concentric lamellar bone.  
Trabecular (cancellous) bone is a network of interconnecting trabecules orientated in 
a position to provide maximum strength for minimum mass. Trabeculae have a thin 
external layer of endosteum containing flat inactive osteoblasts. They are composed 
of lammelar bone with scanty lacunae containing osteocytes. These spaces 
exchange metabolites via canaliculi, which communicate with each other and with 
blood sinusoids in the haematopoietic (red) marrow spaces.  
For most bones, we can determine a thick rigid outer shell of compact bone, the 
cortex, and a central medullary or cancellous zone of thin interconnecting narrow 
bone trabeculae. The number, thickness and orientation of the trabecular bone 
depends on the stress to which a particular bone is exposed. For example, there are 
many thick intersecting trabeculae in the constantly weight-bearing vertebrae, but 
very few in the centre of the ribs, which are not subjected to constant stress (Young 
et al. 2013). 
1.1.2. Types of bones 
Long bones – these are the bones of the extremities. The middle part of the bone is 
called the diaphysis, and the two ends of the bones are called the epiphysis. The 
external surface of the bone is enveloped in a dense fibrous layer called the 
periosteum, into which muscles, tendons and ligaments are inserted. The articular 
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surfaces of the epiphyses of long bones are protected by a layer of specialized 
hyaline cartilage, called articular cartilage. In the middle of the bone there is a pulp 
cavity, which in adulthood is filled with yellow bone marrow. Lengthening of the long 
bones by the process of endochondral ossification occurs at a epiphyseal plate 
situated at each end of the bone at the junction of the diaphysis and the epiphysis 
(for example the femur).  
Short bone – the structure is no different from that of the long bones, but all the 
dimensions are approximately the same. For example, vertebrae.  
Flat bone - on the outer and inner parts, flat bone has compact bone of different 
strengths, filled with cancellous bone with large trabeculae. Well into old age, the 
spaces are filled with red bone marrow (for example, shoulders, ribs and the pelvis) 
(Young et al. 2013). 
1.1.3. Bone repair and remodeling 
Bone regeneration is a complex of physiological processes of bone induction and 
conduction, involving several following stages with a numerous cell types and 
intracellular and extracellular molecular-signalling pathways (Dimitriou et al. 2011).  
At the bone healing site, a blood clot first forms. During bone fracture integrity of 
bone tissue is damaged associated with rupture of blood vessels. The blood flowing 
into the site of injury forms hematoma (Kolar et al. 2010). Platelets activate 
coagulation cascade and mediate fibrin clot formation and provide hemostasis 
(Figure 1). They also stimulate inflamantation process by interaction with immune 
cells (May et al. 2008) and secretion of numerous growth factors (Karshovska et al. 
2013). Growth factors bind to the cell surface and stimulate cell proliferation and 
differentiation. Main growth factors present in bone regeneration include basic 
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fibroblast growth factor (bFGF) which stimulates mesenchymal stem cell proliferation 
and maintain their differentiation potential (Ahn et al. 2009). Bone morphogenic 
proteins (BMPs) which play crucial role during early phases of osteogenic 
differentiation. Proosteogenic BMPs promote expression of early osteogenic markers 
(e.g. connective tissue growth factor (CTGF), inhibitor of DNA binding (ID) and Core 
binding factor alpha 1(Cbfa1)/Runt related transcription factor 2 (RunX2) in MSCs 
and stimulate their proliferation (Mehta et al. 2012). Among the most prominent 
proosteogenic BMPs we include BMP-2 and BMP-7. In addition, insulin-like growth 
factor – I (IGF-I), an antiapoptotic growth factor, also plays an important role in 
osteogenic differentiation of MSCs. The combination of rapid growth factor production 
and hypoxic conditions in the site of injury stimulate angiogenesis, which facilitates 
better distribution of nutrients, oxygen, pro-healing factors and exchange of waste 
products. Beside inflamantory and pro-angiogenetic role, the secreted cytokines and 
chemokines also stimulate activation and migration of progenitor cells. MSCs then 
differentiate into chondroblasts and progressively replace the fibrous granulation 
tissue with hyaline cartilage. This bridge, which is still flexible, is known as a 
provisional callus. The provisional callus then has calcium salts deposited within the 
cartilage matrix. Meanwhile, activated osteoprogenitor cells in the endosteum and 
periosteum lay down a meshwork of woven bone within and around the provisional 
callus. The provisional callus is transformed into a bony callus. Bony union is 
completed when the fracture site is fully bridged by woven bone. The remodelling of 
the bony callus to form mature lamellar bone is dependent on functional stresses 




Figure 1: Cell signalling and cell proliferation during wound healing cascade. PDGF, VEGF, 
and TGF play integral role in the cell migration. BMP releasing from the bone matrix play key 
role during early phases of osteogenic differentiation into osteoblast and chondrocytes 
(Hollinger et al., 2008). 
 
In the first year of life, the rate of turnover of the skeleton approaches 100% per 
year. The rate declines to about 10% per year in late childhood, and then usually 
continues at approximately this rate, or more slowly, throughout life, up to the age of 
a hundred years. After skeletal growth has been completed, bone turnover results 
primarily from remodeling. Remodeling is a coordinated cycle of tissue resorption and 
formation over extensive regions of bone and over prolonged periods. Physiological 
remodeling, removal and replacement of bone, at the same location, without affecting 
the shape or the density of the bone, through a sequence of events, is a process that 
includes osteoclast activation, bone resorption, osteoblast activation and also the 






Figure 2: Bone tissue adaption by basic multicellular units executing bone remodelling 
(Pivonka et al., 2008). 
1.1.4. Mechanical properties of bone 
The combination of hard inorganic components and resilient organic components 
results in the excellent mechanical properties of bones. It is fascinating that compact 
bone specimens have tensile strength in the range of 700 to 1400 kg/cm2, and 
compressive strength in the range of 1400 to 2100 kg/cm2, which is the same 
magnitude as for aluminum or mild steel, but bone is much lighter. However, bones 
are characterized not only by significant stiffness. Stiffness, defined by initial modulus 
of elasticity in pressure. Initial modulus is the slope of the stress-strain curve between 
strain 2-10%), defines the edurance of material to the pressure loading. In other 
words, the high value of stiffness (modulus) is related to the high edurance of 
material to pressure, the low value of stiffness is related to the low edurance of 
material to pressure. The same value of pressure deforms more the material with low 
stiffness when compared with high stiffness material.but also by a high degree of 
elasticity, which is important for the ability of the skeleton to withstand mechanical 
stresses. Estimates of the modulus of elasticity of bone samples are of the order of 
420 to 700 kg/ cm2. These are much lower than the values for steel. The great 
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strength of bone is principally along its axis, and is therefor roughly parallel both to 
the axis of the collagen fiber and to the long axis of the mineral crystals (Young 
2013).  
1.1.1.1. Methods for measuring the biomechanical properties of bone 
From the point of view of its structure, bone is a very complex, anisotropic material. 
Here we find structures with macro, micro and nano dimensions. Therefore, there are 
many approaches for investigating and understanding the mechanical properties of 
bone. The greatest advances over old methods have probably been achieved with 
the use of ultrasonic measurements. After some disputes, it is now considered that 
this method is suitable for distinguishing between different types of bone from a 
histological point of view (Malik et al. 2003). Fatigue tests are another approach, 
which is now often applied using a calculation with the Young's modulus. These 
methods work well for materials with a smooth surface and an isotropic structure, but 
they are not fully functional in measuring the properties of materials such as bone. 
Real bones have complicated shapes, rough surfaces, and are more or less tough. 
Fracture mechanics has developed a method that can deal with these problems. The 
method attempts to characterize the tendency of a material to fracture as a material 
property, independent of the geometry of the specimen. It also attempts to determine 
how the actual geometry of the specimen, including the presence of flaws, will affect 
the fracture behavior. An interesting recent development is the concept of the ‘‘R-
curve’’ (Oliver and Pharr 1992). 
Oliver and Pharr (2004) described nanoindentation, a method that has recently 
become widely used for determining the Young’s modulus of very small parts of 
materials. Nanoindentation involves pressing a tiny probe onto the bony surface and 
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simultaneously measuring the load and the deformation. Finite Element Analysis 
(FEA) is one of the most widely used engineering analysis techniques in the world 
today. It originated in the 1970s, when powerful computers began to be widely 
available. FEA is a computer method for determining the strains in loaded models. 
FEA programs range from those that allow only two Young’s moduli in the whole 
system, and assume that the bone material is isotropic, to those that allow many 
Young’s moduli, anisotropy, etc. FEA is particularly useful for determining the strains 
in bones of complex shapes, like skulls and cancellous bone. In the ideal case, we 
can take a shape, digitize it in some way, turn it into an FEA model, attribute elastic 
material properties to each element, load the model with any loading, and see the 
distribution of strains produced in the model. Computer-aided tomography (CT) was a 
technological advance that enabled FEA to progress greatly in studies of bone. In 
micro-CT, the specimen is scanned in virtual slices with an x-ray beam, and an 
algorithm allows the density of various parts of the object to be calculated. The slices 
are then amalgamated to produce a 3- dimensional (3D) density image of the object. 
Each part of the object has both its density and its 3D position rendered objectively in 
numbers, and this data can be turned, almost directly, into an FEA model (Currey 
2012). Interferometry (ESPI, or electronic speckle pattern interferometry) is another 
method that can measure extremely small displacements, but extensive statistical 
techniques must be used to determine strains (Zaslansky et al. 2006). 
1.2. Current treatments for bone defects 
Under physiological conditions of the remodeling process, bone is able to repair itself 
until there is a defect of a critical size. Situations where the critical size is exceeded 
result mostly from trauma, congenital abnormities, infection or tumor resection. 
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Schmitz and Hollinger (1986) defined critical defects for animals as a defect of a size 
that will not heal during the lifetime of the animal. For large defects, human 
interventions are necessary in order to help or stimulate the healing process (Barrere 
et al. 2006). 
The introduction of bone banks and the development of standards in bone 
transplantation raised the false hope that a final solution to the treatment of bone loss 
had been found. However, the use of allografts is unsatisfactory, due to negative 
effects such as allergic reactions, rejection reactions, inflammation and other 
problems. The current standard treatment for damaged tissue is an autograft tissue 
transplant. The material is usually harvested from the iliac crest, the distal femur or 
the greater trochanter. The proximal tibia can also be used (Perry 1999). 
However, this method has several limitations including patient pain, morbidity at 
the harvesting site, and limited availability (Hutmacher 2007). 
Xenografts acquired from animal bone offer another option. However, the 
morphology of the bone is different from that of human bone, and there is a  risk of 
cross-species infection (de la Caffiniere et al. 1998). At the present time, well-
established substitutes are demineralized bone matrix (DBM), composites and 
calcium phosphates (hydroxy apatite and tri-calcium phosphate). These substances 
are widely used for their osteoconductive properties, and have been shown to 
improve the formation of new bone. Although clinical application of these materials 
has been successful where there are favorable bone health conditions, it is not 
effective for large and critical bone defects (Schlickewei and Schlickewei 2007). 
For regenerating critical bone defects, a promising future lies in improving of our 
knowledge about bone healing, osteoconductive and osteoinductive materials, and 
stem cell biology (Hutmacher 2000).  
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1.3. Bone Tissue Engineering 
Better knowledge in material science and technologies, and also in the area of MSCs 
and bioactive molecules has led to new opportunities in the treatment of large bone 
defects. Current approaches involve a combination of osteoconductive, 
osteoinductive and osteogenetic substances, in a biocompatible, bioresorbable, and 
cost-effective bone graft substitute to enhance the advantages and reduce the 
disadvantages of the concepts. 
The term “tissue engineering” first appeared in the literature in the mid 1980s with 
reference to surgical manipulation of tissues and organs or, in a broader sense, when 
prosthetic devices or biomaterials were used. The term “tissue engineering”, as it is 
used nowadays, was introduced into medicine in 1987. The agreed definition was: 
“Tissue engineering is the application of the principles and methods of engineering 
and life sciences toward the fundamental understanding of structure and function 
relationships in normal and pathologic mammalian tissue and the development of 
biological substitutes to restore, maintain, or improve function.” The early years of 
tissue engineering were based on cell and tissue culture approaches (Vacanti 2010; 
Vacanti and Langer 1999). 
Tissue engineering has been considered one of the most promising biomedical 
technologies of the 21st century, since the time when the BBC showed photos of the 
“mouse with a human ear”, which originated in the laboratory of Dr. Charles Vacanti 
from the University of Massachusetts Medical School, published in 1997 (Cao et al. 
1997). This work catapulted tissue engineering to the attention of the research world 
and also to attention of the general public. 
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One of the current strategies is to harvest stem cells from a patient, expand them 
in a cell culture, and seed them on to a scaffold. Current  challenges in tissue 
engineering are how to optimize the isolation, proliferation and differentiation of cells, 
and how to develop osteoconductive and osteoinductive scaffolds. When given 
specific biological stimuli, stem cells can develop into many types of specific mature 
cells via a process called cell differentiation.The scaffold should then support 
proliferation and differentiation of stem cells into the specific cells that will generate 
specific new tissue. The new tissue should grow on a scaffold that will gradually be 
completely resorbed as the new tissue grows. After implantation, the tissue-
engineered construct must be able to survive, restore normal function, e.g. 
biochemistry, mechanical integrity and structural integrity, and integrate with the 
surrounding tissues. In addition, the use of autologous cells eliminates the problem of 
immunorejection that can occur with transplants from donors (Boccaccini 2005). 
1.3.1. Bone tissue engineering scaffolds 
An ideal scaffold should meet the critical parameters needed for bone regeneration, 
e. g. appropriate mechanical, structural, chemical and surface properties. It should be 
biocompatible,  biodegradable at a rate adequate for the remodelling of the bone, 
and also osteoconductive and osteoinductive (Hutmacher 2007; Karageorgiou and 
Kaplan 2005).  
A biocompatible scaffold has a positive influence on cellular activity, facilitating 
molecular and mechanical signalling systems to optimise tissue regeneration, without 
eliciting any undesirable effects in those cells, and without inducing any undesirable 
local or systemic responses in the eventual host. 
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Biodegradable materials are solid polymeric materials which break down due to 
macromolecular degradation and are dispersed in vivo , but it is important to ensure 
that they remove themselves safely from the body after they are dispersed. The mass 
loss is accompanied by an increase in acidic byproducts. Massive release of acidic 
degradation and respiration byproducts can result in inflammatory reactions in vivo. 
Osteoconductive materials stimulate the growth of bone tissue on the implant 
surface. 
An osteoinductive material stimulates osteoprogenitor cells to differentiate into 
osteoblasts, which then initiate new bone formation. 
An osteoinductive and osteoconductive scaffold will serve as a scaffold for existing 
osteoblasts  as well as trigger the formation of new osteoblasts and promote faster 
integration of the graft (Boccaccini 2005; Hutmacher 2007; Karageorgiou and Kaplan 
2005).  
1.3.1.1. Materials and fabrication methods for bone tissue scaffolds 
Increasing knowledge about polymers has led to new opportunities with materials 
and also in fabricating suitable scaffolds for tissue engineering.  
Several biomaterials, including bioceramics, biopolymers, metals and composites, 
have been described as suitable materials for bone tissue engineering scaffolds 
(Bose et al. 2012; Dawson and Oreffo 2008; Hutmacher 2000; Karageorgiou and 
Kaplan 2005). Natural polymers (e.g. collagen, alginate, chitosan, hyaluronic acid, 
fibrin, silk fibroin) have a great advantage because of their biocompatibility and 
biodegradability, and because of their basic original function as the structural 
materials of tissues. However, they have low mechanical strength and high rates of 
degradation, so they have to be used in composites, or to be chemically  modified by 
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cross-linking (Hutmacher 2007). High producibility, controlled reproducibility and low 
cost are major advantages of synthetic polymers (e.g. poly(ε-caprolactone) (PCL), 
poly(lactic-co-glycolic acid) (PLGA), poly(L-lactide-co-ε-caprolactone) (PLCL), 
polyurethanes) (Bose et al. 2012; Hutmacher 2000; Karageorgiou and Kaplan 2005). 
However, limited biocompatibility and a low rate of biodegradability can be limiting 
factors for their use.  
Brittleness and slow degradation rates are disadvantages associated with ceramic 
implants, based mainly on HA (Hutmacher 2000).  
The disadvantages of any material for osteogenic applications can be overcome 
by using it in combination with other materials, i.e. by designing a so-called 
composite material. For example, the addition of HA particles into a collagen scaffold 
improved the mechanical properties of the scaffold (Kim et al. 2004; Lickorish et al. 
2004; Zhao et al. 2002). A number of fabrication technologies have been applied to 
produce 3D polymeric scaffolds with high porosity and a large surface area from 
biodegradable and bioresorbable materials. Solvent casting, particulate leaching, 
freeze drying, membrane lamination and melt holding, as well as rapid prototyping 
technologies, are conventional techniques for fabricating scaffolds fabricated in 
several structural forms such as hydrogels, porous foams and electrospun 
nanofibers.  The fabrication method and use of polymeric scaffolds for bone tissue 
engineering has been reviewed by Bose et al. (2012) and by Rezwan et al. (2006).  
The fabrication process influences the properties of the scaffold. For example, Hu 
et al. (2002) observed that a different morphology of the scaffold caused a different 
amount of water co-solvent content in dioxane. Dioxane contents above 3% (v/v) led 
to interconnected circular pores, but dioxane contents higher than 7% led to fibrous 
polymers with poor handling qualities. Increasing the concentration of the polymer 
24 
 
solution led to a smaller pore size and to diminished porosity  (Hu et al. 2002). 
O’Brien et al. (2004) desribed in their study an influence of freezing rate on pore 
structure in freezedried collagen scaffolds. Higher polymer molecular weight 
increased the median pore size and the porosity (Karageorgiou and Kaplan 2005). 
An ideal scaffold would not only act as a template for tissue growth and have 
control resorbability, but should also promote the activity and migration of cells of the 
tissue for self-regeneration. The scaffold can serve as a delivery system for the 
controlled release of cell- and gene-stimulating agents. A number of different 
bioactive substances can be agents of this kind. Bioactive substances could be 
incorporated into resorbable polymer or hydrogel scaffolds, which would release the 
substances into the body as the scaffold resorbs. Bioactive glasses and silicon-
substituted HA scaffolds could also release silicon and calcium ions in low 
concentrations. These ions have been found to stimulate seven families of genes in 
osteoblasts, increasing proliferation and bone extracellular matrix production 
(Frohbergh et al. 2012). Several techniques are used for chemically modifying the 
surfaces by releasing bioactive molecules such as HA or bioactive glass, for 
example, plasma-sprayed HA coatings and ion beam sputtering (Yang and Chang 
2001; Zyman et al. 1994).Heat treatment then needs to be applied to facilitate 
crystallization of amorphous coated HA to a bioactive crystalline form (Choi et al. 
2000; Yoshinari et al. 1994). However, the very high temperatures that are necessary 
for crystallization are not favorable for nonmetallic materials, such as polymers and 
bioactive molecules. Pulsed laser deposition (PLD) can be an alternative technique 




1.3.1.2. Porosity and pore size  
Porosity and pore size, at the macroscopic level and also at the microscopic level, 
are important morphological properties of a biomaterial scaffold for bone 
regeneration. They play a critical role in bone formation in vitro and in vivo 
(Karageorgiou and Kaplan 2005). 
Porosity is defined as the percentage of void space in a solid (Leon 1998), and as 
a morphological property not dependent on the material. Pores are necessary for 
bone tissue formation and for integration of the surrounding tissue in vivo, because of  
the migration and proliferation of osteoblasts and mesenchymal cells, and also 
because of vascularization (Kuboki et al. 1998). The most common techniques used 
for creating porosity in a biomaterial are salt leaching, gas foaming, phase 
separation, freeze-drying and sintering, depending on the material used to fabricate 
the scaffold (Kuboki et al. 1998).   
On the basis of many studies, the minimum pore size required to regenerate 
mineralized bone is in general considered to be 100 μm, after the study by Hulbert et 
al. (1970). However, subsequent studies have shown better osteogenesis for 
implants with pores ˃300 μm (Gotz et al. 2004; Kuboki et al. 2001; Prosecka et al. 
2011; Tsuruga et al. 1997).  Large pores (100–150 and 150–200 μm) showed 
substantial bone ingrowth. Even pores of smaller size (75–100 μm) resulted in 
ingrowth of unmineralized  osteoma tissue. Smaller pores (10–44 and 44–75 μm) 
were penetrated only by fibrous tissue (Hulbert et al. 1970). These results were 
correlated with normal Haversian systems that reach an approximate diameter of 
100–200 μm (Hulbert  et al. 1970). 
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1.3.1.3. Mechanical properties of scaffolds for bone tissue engineering 
The mechanical properties of the 3D bone scaffold at the time of implantation should 
match that of the host tissue as closely as possible (Hollister et al. 2005). 
The mechanical properties of scaffolds are generally measured by way of their 
compressive properties. A widely-used method for measuring the mechanical 
properties of bone scaffolds is via the Young's modulus, also known as the tensile 
modulus or the elastic modulus, when the Young’s modulus is computed by 
determining the slope of the stress-strain curve along the elastic portion of the 
deformation (Hou et al. 2003; Xiong et al. 2002).  
1.3.2. Nanofibers in bone tissue engineering 
The main reasons why nanofibers are suitable materials for tissue engineering and 
regenerative medicine are the diameters and the orientation of the fibers, which 
correlate with the fibers of the extracellular matrix (ECM) (Liao et al. 2006; Pham et 
al. 2006). Electrospinning is a recent fiber-forming nanotechnology that enables us to 
create submicron fibers drawn from polymer solutions and melts by electrical forces. 
Electrospinning technology can be divided into needle, needleless and core-shell 
methods (Lukas et al. 2009). Electrospun nanofibers are characterized by high 
porosity and by an abundance of interconnected pores. In addition, nanofibrous 
scaffolds exhibit a nanotopography with a large surface-to-volume ratio, facilitating 
cell adhesion and proliferation (Liang et al. 2007; Liao et al. 2006). Due to this unique 
property, nanofibrous scaffolds offer numerous contact points for cells. Further 
advantages of nanofibrous constructs are the versatility of the polymeric materials 
that are used, and the fact that the surface can be chemically modified. Nanofibers 
have diameters similar to the diameter of natural extracellular matrix,  and they can 
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be prepared from biocompatible and biodegradable synthetic polymers, e.g. poly 
(lactic acid) (PLA), PCL, Polyvinyl alcohol (PVA), polyurethanes, or natural polymers, 
such as chitosan, silk fibroin, collagen, hyaluronic acid and cellulose (Li et al. 2005; 
Liang et al. 2007). 
Alongside the favourable properties of nanofibers, there are some major limitations 
to the use of electrospun nanofibers for regenerating critical size defects, due to their 
insufficient mechanical stiffness and their 2- dimensional (2D) structure. It remains a 
challenging task to prepare functional 3D nanofiber scaffolds (Rampichova et al. 
2013). 
More promising systems for 3D tissue regeneration involve the use of nanofibers 
in composite systems, such as polymeric foam/nanofiber composites and 
hydrogel/nanofiber composites. Albanna et al. (2012) used chitosan fibres to improve 
the mechanical properties of chitosan-based heart valve scaffolds. In this study, PCL 
nanofibers prepared in our laboratory improved the mechanical properties of a 
collagen/HA scaffold for bone tissue engineering (Prosecka et al. 2014). 
Many fabrication methods, combinations of materials as well as functionalization of 
scaffolds for bone tissue regeneration for improving of their properties were 
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1.3.2.1. Electrospun nanofibers as a drug delivery system 
Nanofibers have been utilized for delivering both water-soluble and water-insoluble 
substances, and serve as drug delivery systems (Blakeney et al. 2011; Liang et al. 
2007). Due to their enormous surface area, nanofibers enable the adhesion of 
diverse bioactive agents, such as growth factors, enzymes or nucleic acids (Albanna 
et al. 2012; Schofer et al. 2008). The kinetics of the release of the content is 
determined by the form of the interaction between the fibers and the adhered drug. 
However, drugs dissolved or dispersed in the materials from which nanofibers are 
produced are quickly released. Healing processes often require a slower release, 
over a period of days or even weeks. This is especially important in vivo. To 
overcome this obstacle, bioactive substances have been incorporated in the interior 
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of the nanofiber (Sill and von Recum 2008).  Coaxial electrospinning was introduced 
as a novel method for drug delivery, resulting in the production of core/shell 
nanofibers (Jiang et al. 2006). Buzgo et al. and Míčková et al. successfully developed 
a time-regulated drug delivery system based on coaxially incorporated platelet α -
granules for biomedical use (Buzgo et al. 2013) and a drug delivery system based on 
core/shell nanofibers with embedded liposomes (Mickova et al. 2012). 
A very promising approach for 3D tissues, such as bone, is to prepare composite 
scaffolds from microspheres and to combine them with various scaffolding systems, 
including hydrogels, ceramics, titanium implants and polymeric foams (Sahoo et al. 
2010; Venugopal et al. 2008). Microspheres have been used for delivering bioactive 
molecules, e.g. growth factors and drugs (Kempen et al. 2008; Wenk et al. 2009).  
A promising new approach, described by Knotek et al., was a suitable method for 
preparing a nano-/micro-mesh via cryogenic grinding (Knotek et al. 2012). 
The release of substances from nanofibers in vitro and in vivo has been described 
in recent studies (Kouhi et al. 2013; Martins 2010; Su et al. 2012; Zhu et al. 2013). 
1.3.3. Growth factors 
Improved understanding of growth factor action and molecular signalling pathways 
has opened opportunities for novel therapeutic options. General growth and 
differentiating factors involved in bone regeneration include BMPs, transforming 
growth factor-β1 (TGF-β1) and TGF-β2, IGF-1, platelet-derived growth factor 
(PDGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor 
(VEGF) and epidermal growth factor (EGF). Other proteins, such as fibrin, fibronectin 
and vitronectin support cell adhesion, osteoconduction and matrix formation. In 
addition, small molecules, such as hydrocortisone, dexamethasone, and β-glycerol 
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phosphate and synthetic growth factor are involved in osteogenesis (Dohan 
Ehrenfest et al. 2009; Wasterlain et al. 2012). 
Novel approaches are focused on the application of autologous platelet rich 
plasma (PRP) and its derivatives, mainly α-granules (Blair and Flaumenhaft 2009). 
These blood derivatives contain autologous growth factors that are involved in 
cartilage and bone growth, and that in addition eliminate adverse immunogenic 
reactions. Autologous PRP has already been used in clinical applications for their 
stimulating effect on cells and tissue healing, even without cell therapy (Mazor et al. 
2004).  
The positive effect of a combination of MSCs and PRP on bone healing and 
remodeling have been described in many studies (Chen et al. 2012; Kitoh et al. 
2004). Clearly, TGF-β1 and TGF-β2, as a part of PRP, are general growth and 
differentiating factors involved in bone regeneration via the mitogenesis of osteoblast 
precursors, and are also involved in inhibiting osteoclast formation and bone 
resorption. IGF-1 accelerates bone formation  via increasing the number of 
osteoblasts. In addition, PRP contains three important proteins in blood - fibrin, 
fibronectin, and vitronectin - which act as cell adhesion molecules for 
osteoconduction and as a matrix for bone, connective tissue, and epithelial 
development (Dohan Ehrenfest et al. 2009; Wasterlain et al. 2012; Wrotniak et al. 
2007).  
 Currently, several key factors, such as the positive effect of leucocytes or fibrin 
and a suitable and reproducible way to prepare PRP, are still under discussion. 
(Wasterlain et al. 2012). In several studies whole PRP has been compared, for 
example, with PPP (platelet poor plasma), which includes only blood plasma. 
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Pietrzak et al. (1997) found improved wound healing for PPP in comparison with 
untreated controls in vivo, but it was not as effective as PRP.  
Injecting growth factors into the site of the defect is one of many approaches. 
However, these systems are rather difficult to apply in clinical practice,  due to rapid 
diffusion of active substances away from the site of tissue regeneration (Tabata 
2000). This problem can be solved by using a suitable biocompatible scaffold, which 
is able to carry the particular growth factors. The functionalization of biomaterials with 
growth factors has been well documented in several studies. For example, 
Swiontowski et al. used high doses of osteo-inductive BMP-2 loaded onto degradable 
collagen sponge matrices for bone regeneration (Swiontkowski et al. 2006). 
However, no system has yet been devised that can deliver the growth factors directly 
into the defect, protect the bioactivity of the growth factors and control their release in 
a suitable manner. 
1.3.4. Cells in bone tissue engineering 
Primary osteoblasts, osteosarcoma cell lines and osteoprogenitor cells have been 
used for in vitro or in vivo testing of bone tissue engineered constructs (Mendes et al. 
2002). Each of them has its pros and cons. For example, the pluripotency of 
osteoprogenitor cells decreases with passage numbers. However, cell lines that 
provide more reproducible results may not represent the real situation (Rochet et al. 
2003).  
Stem cell biology has become an important topic in regenerative medicine. Stem 
cells are undifferentiated cells with the ability to divide in a culture and give rise to 
different forms of specialized cells. They are found in multicellular organisms. 
According to their source, stem cells are divided into "adult" and "embryonic" stem 
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cells. Embryonic stem cells are isolated from the inner cell mass of blastocysts, and 
adult stem cells are found in various tissues. In adult organisms, stem cells and 
progenitor cells act as a repair system for the body, replenishing adult tissues 
(pluripotent cells). In a developing embryo, stem cells can differentiate into all the 
specialized cells (ectoderm, endoderm and mesoderm), but they also maintain the 
normal turnover of regenerative organs, such as blood, skin, and intestinal tissues 
(multipotent cells) (Vernon et al. 2012).  
Although embryonic stem cells seem to be the gold standard in stem cell research, 
there is still a large ethical debate about their use (Melville et al. 2006). Therefore, 
Bone-marrow derived MSCs are considered to be the most researched post-natal 
stem cells. They can be isolated from numerous tissues throughout the body, e.g. 
bone marrow, adipose tissue, muscle, periosteum, dental tissue, umbilical cord, etc. 
(Campagnoli et al. 2001; Gronthos et al. 2002; Seo et al. 2004; Schugar et al. 2009; 
Zuk et al. 2002).  
Under suitable conditions, stem cells clearly have the potential to differentiate cell 
lineages and thus to play a key role in tissue engineering and regenerative medicine.  
Stem cells can differentiate into osteogenic lineages when cultured in the presence of 
dexamethasone, ascorbic acid and β-glycerophosphate (Dawson and Oreffo 2008) 
and can potentially be used for treating large bone defects (Vernon et al. 2012). 
Autologous stem cells as a source of donor cells have numerous advantages for 
regenerative medicine. These include low donor site morbidity, a diminished or 
absent immune response, and high proliferative potential (Cancedda 2003; Stevens 
et al.  2008).  
It is still an open question which cell type to focus on in order to understand the 
whole process of bone regeneration, and which cell type is the most suitable for a 
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tissue engineering approach. A new strategy is focused on co-culture systems. For 
example, Rochet et al. solved the problem of insufficient vascularization of bone 
tissue-engineered constructs via co-cultures of  MSCs with endothelial cells. Co-
cultures are initiated in order to stimulate vascularization and bone formation 
simultaneously (Rochet et al. 2002).  
De Boer et al. have recently addressed another example of co-cultures, the 
application of transgenic luminescent cell cultures coupled with MSCs (de Boer et al. 
2006).  
1.3.4.1. Static and dynamic cultivation of cells 
Control of the hydrodynamic and biochemical environment is essential for the 
successful in vitro engineering of 3D scaffold/tissue constructs for potential clinical 
use (Hutmacher 2000).  
Gradients in tissue quality emerge, including inhomogeneous cellular proliferation 
and differentiation from outer areas of the scaffolds toward the center with increasing 
size of the cell-seeded scaffold.  In vivo, the distance between cells and capillaries, 
which provide nutrients and oxygen and at the same time account for waste 
elimination, ranges from 20 to 200 um (Malda et al. 2007; Malda et al. 2004; Malladi 
et al. 2006; Muschler et al. 2004). In vitro, sufficient nutrition and oxygenation of cells 
by diffusion is limited to a distance of 100–200 um, because of poor difusion capacity 
and solubility in aqueous solutions of oxygen (Carrier et al. 2002; McClelland and 
Coger 2000).  
 It has been hypothesized that hypoxia is the limiting factor in scaling up 3D 
cultures in vitro. Various cellular mechanisms, including the cell cycle, cell 
proliferation, apoptosis, and the glucose metabolism are influenced by oxygen 
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concentration (Wang et al. 2007). Recent studies have observed that the process of 
osteogenic differentiation and new bone tissue development are also highly 
dependent upon the oxygen level (Wang et al. 2007). Bioreactors offer a a promising 
solution to the diffusional limitations of a static culture, and a way to control the 
cultivation environment (Abousleiman and Sikavitsas 2006; Martin and Vermette 
2005; Schumacher et al. 2010). A fluid dynamic microenvironment provided by a 
bioreactor can mimic the interstitial fluid conditions present in natural bone in a 
macroporous scaffold architecture. Bioreactors serve larger and better organized 3D 
cell communities in in vitro cultures than can be achieved using standard tissue 
culture techniques (Freed et al. 1998; Goncalves Fda et al. 2012; Schumacher et al. 
2010).  
In general, bioreactors are designed to perform at least one of the following 
functions: provide uniform cell distribution, continuously supply physiological nutrients 
and gases and regulate the required cell/tissue culture conditions for a long period of 
time, provide mass transport to the tissue, expose tissue to physical stimuli, provide 
information about the formation of 3D tissue (Barron et al. 2003). Many systems have 
been developed for the specialized requirements of targeted tissue, including spinner 
flask bioreactors, rotating wall bioreactors, compression bioreactors, strain 
bioreactors, hydrostatic pressure bioreactors and flow perfusion bioreactors (Kasper 
et al. 2007). In addition, numerous combinations of various types of bioreactor have 
been used in order to better mimic the in vivo environment in vitro. For example, a 
combination of compression, tensile strain or hydrostatic bioreactors with added 
perfusion (Carver and Heath 1999; Watanabe et al. 2005). Plunkett and O'Brien 
(2011) described how a combination of a perfusion period for nutrient delivery and 
waste removal and a stimulation period may deliver enhanced fluid transport with 
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2. The aims of the study 
The work presented in this thesis is focused on the following topics: 
1. Find the optimal composition for a bone scaffold 
2. Functionalize the scaffold with bioactive molecules 
3. Test the scaffold in vitro and in vivo 
4. Design a suitable scaffold with potential for clinical use, as an outcome of the   
    experiments  
 
The experimental part of the manuscript describes three experiments, two in vitro and 
















3. Experiments  
As has been mentioned above, bone is a structure composed of a mineral phase 
formed by Ca10(PO4)6(OH)2 crystals of HA deposited within an organic matrix (≈95% 
is type I collagen) (Marks and Odgren 2002). Collagen and HA are widely used 
scaffold materials for bone regeneration, because of their excellent biocompatibility 
with hard tissues, high osteoconductivity, bioactivity, and noncytotoxicity 
(Karageorgiou and Kaplan 2005; Sukhodub et al. 2004). However, although many 
reports have been presented, the optimal collagen/HA ratio for bone regeneration, 
especially for MSCs, remains unclear (Bandyopadhyay-Ghosh 2008; Liu et al. 2007; 
Roveri et al. 2003; Serre et al. 1993; Wahl and Czernuszka 2006). In addition, the 
effect of the collagen/HA ratio on the mechanical parameters of a scaffold, and also 
on cell adhesion and proliferation, is not well established. The main focus of the first 
experiment (Experiment I) presented here was therefore to determine the effect of 
the collagen/ HA ratio on the scaffold structure, and also on the seeding, adhesion 
and proliferation of MSCs differentiated into osteoblasts. 
Cells, especially autologous cells, and smart (functionalized) scaffolds enriched 
with bioactive molecules, preferentially serving as a controlled delivery device, 
represent a new approach in bone tissue engineering (Cancedda 2003). 
Improved understanding of growth factor action and molecular signalling pathways 
has opened opportunities for novel therapeutic options. For most tissue engineering 
approaches, it is necessary to apply appropriate growth factors concentrations with 
cells and an optimal scaffold to trigger the sequence of overlapping events required 
for tissue formation and growth (Prosecka et al. 2014). 
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PRP has excellent properties for tissue engineering and regenerative medicine (Bi 
et al. 2010; Kitoh et al. 2004). PRP releases multiple growth factors such as PDGF, 
TGFβ, FGF, VEGF, IGF-1, and EGF, and is expected to have a tissue regeneration 
rate higher than that of single growth factors (Bi et al. 2010; Everts et al. 2006). 
Platelets also have an important role in the complex local inflammatory response, 
promote angiogenesis (Simpson et al. 2006), and recruit mesenchymal cells (Veillette 
and McKee 2007).  
The key parameters for scaffolds for suitable bone regeneration are their 
mechanical properties. A combination of 3D matrix and nanofibers can improve the 
mechanical properties of the scaffold (Albanna et al. 2012).  The aim of the second 
experiment (Experiment II) was to optimise the previously reported composite 
collagen/HA foam scaffolds (Prosecka et al. 2011) from a biomechanical point of 
view, and enrich them with proliferation and differentiation factors suitable for clinical 
applications. A 3D scaffold of type I collagen and HA functionalized with PCL 
nanofibers (Coll/HA/PCL) to strengthen the mechanical properties of the scaffold and 
enriched with autologous MSCs in osteogenic media, and a thrombocyte rich solution 
(TRS) to increase the osteoinduction and osteoconduction of the scaffold was 
prepared and tested in vivo in an experimental rabbit model.  
The nanofibers can not only be modified on their surface but also enriched in their 
core with various drugs that can be released slowly over the course of days or 
weeks. The aim of the third Experiment (Experiment III) was to find a suitable surface 
modification, which an essential step in constructing artificial cell-seeded systems. 
HA, which is similar to the apatite of living bone, can be used as a suitable material 
for improving cell proliferation and differentiation into osteoblasts (Karageorgiou and 
Kaplan 2005; Kuboki et al. 1998). Coating bone implants with HA improves the 
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osteoinductivity of the scaffolds and promotes ingrowth of the surrounding bone 
tissue into the implant (Ducheyne et al. 1990; Klein et al. 1991; Tisdel et al. 1994). A 
number of techniques are used for producing thin HA films. Each of them has its pros 
and cons. For example, plasma-sprayed HA coatings, where the HA is bound 
mechanically, have limited chemical bonding, and cracks, pores and other impurities 
limit their mechanical strength in contact with a substrate and the stability of the layer 
(Yang and Chang 2001; Zyman et al. 1994). Another coating technique is ion beam 
sputtering, which produces an amorphous coating. Heat treatment is subsequently 
necessary to produce crystals (Choi et al. 2000; Yoshinari et al. 1994). The very high 
temperatures that are necessary for crystallization are not favourable for thermo 
sensitive materials, such as polymers and bioactive molecules. Pulsed laser 
deposition (PLD) is used as an alternative HA coating technique (Bao et al. 2005; 
Blind et al. 2005). PLD employs an intense laser beam to evaporate the material. 
Subsequent condensation on a mat can form a very thin layer (only a few atoms in 
depth).  
A comparison of different thicknesses of the HA layer deposited on the surface of 
nanofibers was studied in Experiment III. In addition, the study confirmed the 
promising potential of coaxial PCL/PVA nanofibers, e.g. as a drug delivery system 




3.1. Experiment I  
Optimized conditions for mesenchymal stem cells to differentiate 
into osteoblasts on a collagen/ hydroxyapatite matrix 
Collagen/HA composite scaffolds are known to be suitable for seeding with MSCs 
differentiated into osteoblasts, and for the in vitro production of artificial bones. 
However, the optimal collagen/HA ratio remains unclear. We demonstrate in our work 
the influence of the different collagen/HA ratio on cell adhesion, proliferation and 
differentiation, and the mechanical properties of the scaffold.  
3.1.1. Methods I 
3.1.1.1. Scaffold preparation  
Bovine collagen type I was supplied as an 8 wt % aqueous solution (VUP, Brno, CZ) 
and was freeze-dried (ALPHA 1-4 LSC, CHRIST, -55º C, 15 Pa, and 24 h) to obtain 
100% pure collagen I. HA was used in the form of a nanoparticle powder with an 
average particle size of 350 nm (Research Institute of Inorganic Chemistry, Usti nad 
Labem, CZ). N-(3-dimethylamino propyl)-N’-ethylcarbodiimide hydrochloride (EDC) 
and N-hydroxysuccinimide (NHS) (Sigma Aldrich, Germany), used as cross-linking 
agents, and Na2HPO4.12 H2O, used as a washing agent, were diluted in water and 
used as received. Collagen solutions with concentrations of 0.5 (Col0.5/HA50), 1 
(Col1.0/HA50), 1.5 (Col1.5/HA50), or 2 (Col0.5/HA50) wt% were prepared from 
lyophilized collagen in distilled water using an IKA disintegrator at 8000 rpm. The 
solutions were subsequently centrifuged for 5 min at 2879 x g to remove air bubbles. 
Defined collagen solutions were then mixed in the disintegrator with a calculated 
amount of HA powder for 1 min to prepare 30 (Col0.5/HA30), 40 (Col0.5/HA40), 50 
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(Col0.5/HA50), 60 (Col0.5/HA60), or 70 (Col0.5/HA70) wt% mixtures of HA in the 
collagen solutions. The mixtures were placed in a glass Petri dish and were allowed 
to remain until the air bubbles disappeared without centrifugation. The homogenized 
mixtures were frozen at -35º C in 24-well culture plates  for 24 h and were then 
lyophilized at -55º C and 15 Pa for 24 h. The lyophilized porous collagen-based 
scaffolds were cross-linked by an ethanol solution containing EDC and NHS. After 
cross-linking, the samples were washed in a solution of Na2HPO4.12 H2O and finally 
in distilled water, followed by lyophilization at -55º C and 15 Pa for 24 h. The 
morphology of the lyophilized cross-linked collagen scaffolds was observed with a 
Philips Quanta 200 scanning electron microscope (SEM) (Figure I/1). On the sample 
surface, a conductive layer of 3–4 nm was steamed by a Polaron SC7640 sputter 
coater before analysis. The pore size of the collagen matrices and the size of the 
pores were characterized from the images, using the MATLAB image analysis 
program.  
3.1.1.2. Isolation, separation, and cultivation of pig MSCs 
Blood marrow aspirates were obtained from the os illium (tuber coxae ala osis illi) of 
anesthetized miniature pigs (age 6–12 months). The bone marrow blood was 
aspirated into a 10-mL syringe with 5 mL Dulbecco’s phosphate-buffered saline 
(PBS), 2% fetal bovine serum (FBS, StemCell Technologies), and 25 IU heparin/mL, 
connected to a bioptic needle (15 G/70 mm). Under sterile conditions, the bone 
marrow blood (about 20 mL) was deposited over 15 mL of Ficoll-Paque PLUS 
(StemCell Technologies). After centrifugation at 400 x g for 30 min at room 
temperature, the dense gradient separated erythrocytes and granulocytes as a pellet 
in the bottom part of the tube; mononuclear cells were localized in an opalescent 
layer between the Ficoll and the blood plasma. This layer was removed, washed in 
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culture medium (see below), and used for propagation under in vitro conditions. Cell 
numbers and viability were analyzed using a Vi-CELL (Series Cell Viability 
Analyzers), and about 99% viable cells were found. The cells were seeded in tissue 
culture flasks at a density of 800.000 cells/cm2 and cultured at 37º C in a humidified 
atmosphere with 5% CO2 Minimum Essential Media (MEM) medium with Earle’s salts 
with L-glutamine (PAA), supplemented with 10% FBS, and penicillin/streptomycin 
(100 I.U./mL and 100 μg/mL, respectively) was used as the culture medium. MSCs 
seeding on scaffolds 6 mm in diameter and 10 mm in thickness were sterilized using 
plasma sterilization. Before seeding with MSCs, the scaffolds were de-aerated and 
incubated in a differentiation medium (MEM with L-glutamine, 20% FBS, 100 I.U./mL 
penicillin, and 100 μg/mL streptomycin), supplemented with 100 nM dexamethasone, 
40 μg/mL ascorbic acid-2-phosphate, and 10 nM glycerol 2-phosphate disodium salt 
hydrate, at 4–8ºC for 14 days. Cells were seeded on scaffolds at a density of 70 x 
103/ cm2 in 96-well plates and centrifuged at 7 x g for 20 min. Scaffolds with seeded 
MSCs were cultivated in differentiation media supplemented with 10% FBS. The 
medium was changed every 3 days. 
3.1.1.3. Cell adhesion on scaffolds 
Staining with the DiOC6 (3,3-diethyloxacarbocyanine iodide) fluorescent probe was 
used to detect the adhesion of cells on the scaffolds. Samples were fixed with frozen 
methyl alcohol (-20ºC) for 10 min and rinsed with PBS. Subsequently, DiOC6 (0.1–1 
μg/mL in PBS, pH 7.4) was added and incubated with the samples for 45 min at room 
temperature. The samples were rinsed with PBS (pH 7.4), and proprium iodide (5 
μg/mL in PBS, pH 7.4) was added for 10 min; they were then rinsed with PBS (pH 




3.1.1.4. Cell viability analysis by the MTT test 
The MTT test was used for in vitro measurements of the metabolic activity of the 
cells. MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] is 
reduced to purple formazan by mitochondrial dehydrogenation in cells, indicating a 
normal metabolism. 50 μL of MTT (1 mg/mL in PBS, pH 7.4) were added to the 
medium (150 μL), and the samples were further incubated at 37ºC for 4 h. Formazan 
crystals were solubilized with 100 μL of 50% N,N-dimethylformamide/20% sodium 
dodecyl sulfate (SDS)/H2O, pH 4.7. 200 μL of the suspension were removed, and the 
optical density of the formazan was measured (sample 570 nm and reference 690 
nm). The absorbance of the samples incubated without cells was deducted from the 
absorbance of the cell-seeded samples (Figure I/ 3). 
3.1.1.5. Cell viability analysis by the Live/dead staining 
Confocal microscopy and live/dead staining (BCECF-AM/ propidium iodide) were 
used to determine cell viability. 2,7-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein 
acetoxymethyl ester (BCECF-AM, diluted 1:100 in medium) was added to scaffolds 
containing seeded cells and incubated for 45 min at 37ºC and 5% CO2 for live cell 
detection. After rinsing with PBS (pH 7.4), propidium iodide (5 μg/mL in PBS, pH 7.4) 
was added for 10 min, and then the scaffolds were rinsed again with PBS (pH 7.4) 
and visualized using a Zeiss LSM 5 DUO confocal microscope. For each scaffold, the 
number of live/dead cells was counted (Ellipse software) and averaged. Viability was 
calculated as the percentage of live cells from the total cell number in a defined area 




3.1.1.6. Detection of osteogenic marker by Imunofluorescent staining 
Using indirect immunofluorescent staining, OC and type I collagen were detected as 
markers of osteogenic differentiation. Samples were fixed with 10% 
formaldehyde/PBS for 10 min, washed in PBS, and then incubated in 3% FBS in 
PBS/0.1% Triton at room temperature. The primary antibody against OC (mouse anti- 
OC, Abcam, USA) or against type I collagen (mouse antiprocollagen type I, 
Developmental Studies Hybridoma Bank, USA) was diluted 1:20 and added to the 
samples for 1 h at room temperature. Then, the samples were washed with 
PBS/0.05% Tween for 3, 10, and 15 min. The secondary antibody (Alexa Fluor 635-
conjugated goat anti-mouse IgG, Invitrogen) was diluted 1:300 and added for 45 min 
at room temperature. After washing, an antifading solution was added [PBS/90% 
glycerol/2.5% 1,4-diazabicyclo( 2,2,2)octane]. OC staining was visualized using a 
ZEISS LSM 5 DUO confocal microscope (Figure I/ 4 e, f, g, h).  
3.1.1.7. Quantitative real-time PCR analysis 
Total RNA was extracted using an RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. This kit is based on a technology that combines the 
selective binding properties of silica-gel-based membranes with the speed of 
microspin technology. After the end of the procedure, total RNA was stored at -20ºC. 
The cDNA from 1μg of total RNA was used as a template. Synthesis of cDNA was 
performed by a standard procedure described in our previous work (Tvrdik et al. 
2005). OC and bone sialoprotein (BS) mRNA expression levels were quantified by 
means of a LightCycler 480 (Roche Diagnostics, Mannheim, Germany) using the 
double-strand-specific dye SYBR Green I (Roche Diagnostics, Mannheim, Germany) 
according to the manufacturer’s protocol. The following primers were used: BS, 
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sense 5-CGA CCA AGA GAG TGT CAC-3, antisense 5-GCC CAT TTC TTG TAG 
AAG C-3 (498 bp); OC, sense 5-TCA ACC CCG ACT GCG ACG AG-3, antisense 5-
TTG GAG CAG CTG GGA TGA TGG-3  (204 bp) and beta-actin, sense 5-AGG CCA 
ACC GCG AGA AGA TGA CC-3, antisense 5-GAA GTC CAG GGC GAC GTA GCA 
C-3 (332 bp). The quantitative real-time polymerase chain reaction (real- time PCR) 
conditions were as follows: initial denaturation at 95ºC for 10 min, followed by 45 
cycles of denaturation at 95ºC for 15 s, annealing at 54ºC for 10 s, and extension at 
72ºC for 20 s. The expression levels of OC and BS mRNA were adjusted using the 
level of beta-actin or phosphogycerate kinase (PGK) mRNA as housekeeping genes 
and expressed as the ratio of OC or BS to actin or PGK, respectively. The evaluation 
of the expression of OC and BS mRNA was performed using quantitative real-time 
PCR analysis (p < 0.05, two-sided t-test) (Figure I/ 5, 6). 
3.1.1.8. Mechanical testing of the scaffolds 
The Young’s moduli of elasticity of the porous bone scaffolds under compression 
were obtained at room temperature, using a Zwick/Roel traction machine equipped 
with a 1 kN load cell. The loading velocity was 1 mm/min, in accordance with the 
studies of Narbat et al. (2006) and Olah et al. (2006). 
The specimens were cylindrical in shape (about 12 mm in height and 12 mm in 
diameter). Five samples and 10 measurements were performed in each experiment. 
Mechanical loading was applied until the scaffold was compressed to 75% of its 
original thickness. The compressive moduli were determined by applying linear 
regression to part of the stress–strain curves at 2–10% strain (initial modulus Einit). 
The stress was defined as the force divided by the initial area, and the strain was 
defined as the deformation of the sample (thickness) divided by the initial thickness of 
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the specimen. Our own software written in Python, an Open Source object-oriented 
programming language, was used for the evaluation (elfpy2010). This software 
enables a semiautomatic evaluation of mechanical measurements, namely finding 
the moduli of elasticity, ultimate stresses, and strains. Pressure or tension loading 
with various loading variations can be used, e.g. cyclic loading, loading with linear 
elongation, or loading up to rupture. Text files obtained from the measurement device 
with force, elongation, and time records can be loaded and processed by the 
software. The stresses and strains can be determined by defining the initial areas of 
the measured specimens, as was mentioned above. The software can be left to find 
the almost-linear parts of the stress–strain curves automatically and, by using the 
linear approximation of these parts, to determine the moduli of elasticity. The regions 
used for the linear approximation can also be set by the user. For ressure 
measurements of the bone scaffolds, a user-defined region was used, determined as 
the region of strain between 2 and 10%, and the initial modulus was computed (Table 
I/  1). 
3.1.1.9. Statistical analysis 
Quantitative data is presented as mean/standard deviation (SD). For the in vitro tests, 
the average values were determined from at least three independently prepared 
samples. The results were evaluated statistically using one-way analysis of variance 
(ANOVA) and the Student–Newman–Keuls method. Statistica base 9.1 (Statsoft, 
Tulsa, OK) was applied to the results of the mechanical measurements. The 
normality of the data was tested with the Shapiro–Wilk W test. The correlation 
between the Young’s moduli of elasticity and the amount of collagen and HA, 




3.1.2. Results I 
3.1.2.1. SEM of the Col I/ HA composite scaffold 
The morphology of the lyophilized cross-linked collagen scaffolds was observed with 
a Philips Quanta 200 scanning electron microscope (SEM) (Figure I/1).  
 
Figure I/ 1: SEM of the Col I/ HA composite scaffold. The presence of Col 0.5/HA 50 in a 
composite scaffold (a) resulted in a pore size of 405±74, while Col 2.0/HA 50 (b) resulted in 
an average pore size of 108±28. Quantitative data is presented as mean ± SD. Average 
values were determined from at least three independently prepared samples. 
3.1.2.2. Adhesion of MSCs 1 day after scaffold seeding 
MSCs were adhered on all of the samples. The significantly greatest adhesion was 




Figure I/ 2: Adhesion of MSC 1 day after scaffold seeding. The MSCs on the scaffolds 
were stained with a DiOC6 fluorescent dye to vizualize the living cells. The areas covered by 
adhered cells were measured using a confocal microscope and Ellipsa software. Areas 
containing 100 cells were measured and averaged for each scaffold. Error bars refer to SD. 
The results were evaluated statistically using one-way analysis of variance (ANOVA) and the 
Student–Newman–Keuls method. Significant differences (p < 0.05) were observed: 
Col0.5/HA50 > Col0.5/HA40 > Col0.5/HA60 > Col0.5/HA70> Col1.0/HA50 > Col1.5/HA50> 
Col0.5/HA30, Col2.0/HA50.   
3.1.2.3. Cell proliferation by the MTT test 
Despite the lower cell adhesion, the composite scaffold containing 40% HA 
(Col0.5/HA40), displayed similar cell proliferation 28 days after seeding as did the 
scaffolds composed of Col0.5/HA50. Similar results were also observed for the 
composite samples containing 50% HA in the presence of 1.0% collagen 
(Col1.0/HA50). By contrast, the composite scaffolds containing 70% HA and, in 
particular, 30% HA (Col0.5/HA70 and Col0.5/HA30) were much less efficient in terms 
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of cell proliferation. The Col0.5/HA30 scaffolds were eliminated from further testing 
because of insufficient cell adhesion and proliferation (Figure I/ 3). 
 
 
Figure II/ 3: Cell proliferation by the MTT test. Proliferation of differentiated MSCs (MTT 
test) 7, 14, 21, and 28 days after scaffold seeding. The error bars refer to SD. The results 
were evaluated statistically using one-way analysis of variance (ANOVA) and the Student–
Newman–Keuls method. Significant differences (p < 0.05) were observed: day 7: 6 > 2 > 7 > 
8 > 3 > 1 > 4 > 5; day 14: 6 > 7 > 2, 3, 4 > 5 > 1, 8; day 21: 2 > 3 > 6, 4 > 5 > 7 > 1; day 28: 2 
> 3, 6 > 4 > 5 > 1, 7, 8. 
3.1.2.4. Cell viability and osteogenic differentiation 
Cell viability and osteogenic differentiation were detected by confocal microscopy. 
The highest viability was again detected on the Col0.5/HA50 scaffolds after 28 days 
of cultivation and deteriorated with higher concentrations of both collagen and HA. 
Both OC and type I collagen were present in all samples. The highest concentration 
of proteins was again detected on the Col0.5/HA50 scaffolds 28 days after seeding, 




Figure I/ 4: Cell viability and osteogenic differentiation by confocal microscopy. 
Fluorescence confocal microscopy of differentiated MSCs. Viability of cells by live/dead 
staining (BCECF-AM/propidium iodide) 28 days after seeding: Col0.5/HA50 scaffold (a), 
Col0.5/HA70 (b), and Col2.0/HA50 (c). Immunofluorescent detection of OC 28 days after 
seeding: Col0.5/HA50 scaffold (d), Col0.5/HA70 (e), and Col2.0/HA50 (f). 
3.1.2.5. Quantitative Real-time PCR analysis  
The concentration of OC and BS were analyzed by quantitative real-time PCR 
analysis at scaffolds with different amounts of HA and Collagen. The increasing 
concentration of OC observed over time demonstrated the gradual differentiation of 
MSCs into osteoblasts. The highest production of OC was observed for the 
composite scaffolds containing Col0.5/HA40 and Col0.5/HA50 and also Col1.0/HA50. 
However, the Col0.5/HA60 and Col0.5/HA70 scaffolds were also characterized by a 
comparable production of OC. The significantly greatest production of BS was 
observed for the Col0.5/HA50 composite scaffolds 28 days after seeding. The 
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Col0.5/HA 40 samples were also characterized by a significantly elevated production 
of BS compared to the Col0.5/HA60 and Col0.5/HA70 samples (Figure I/ 5, 6).  
 
 
Figure I/ 5: Real-time PCR analysis of scaffolds with different amounts of HA.  
The evaluation of OC and BS mRNA expression 7 and 28 days after seeding, performed by 
quantitative real-time PCR analysis (p < 0.05, two-sided t-test). Beta-actin was used as a 
housekeeping gene control. Due to the very different values, the scale on the Y axis is 
logarithmic. The error bars refer to SD. Significantly different (p < 0.05) values on a given day 
were identified using one-way analysis of variance (ANOVA) and the Student–Newman–
Keuls method: OC: day 7: Col0.5/HA40> Col0.5/HA60, Col0.5/HA70; Col0.5/HA50> 
Col0.5/HA60, Col0.5/HA70; day 28: Col0.5/HA50 > Col0.5/HA40, Col0.5/HA60, Col0.5/HA70; 
BS: day 7: Col0.5/HA40> Col0.5/HA60> Col0.5/HA50, Col0.5/HA70; day 28: Col0.5/HA50> 





Figure I/ 6: Real-time PCR analysis of scaffolds with different amounts of collagen. The 
evaluation of OC and BS mRNA expression 7 and 28 days after seeding, performed by 
quantitative real-time PCR analysis (p < 0.05, two-sided t-test). Beta-actin was used as a 
housekeeping gene control. Due to the very different values, the scale on the Y axis is 
logarithmic. The error bars refer to SD. Significantly different values (p < 0.05) on a given day 
were identified using one-way analysis of variance (ANOVA) and the Student–Newman–
Keuls method: OC: day 7: Col1.0/HA50> Col1.5/HA50> Col2.0/HA50; day 28: Col1.0/HA50> 
Col1.5/HA50> Col2.0/HA50; BS: day 7: Col1.0/HA50> Col2.0/HA50; Col1.5/HA50> 
Col2.0/HA50; day 28: Col1.0/HA50> Col1.5/HA50> Col2.0/HA50.  
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3.1.2.6. Mechanical properties and porosity of the scaffolds 
Scaffolds from different collagen/HA mixtures were tested and the initial Young’s 
moduli of elasticity Einit in compression were determined at strain 2-10%. Note a 
strong positive correlation between collagen concentration and Young’s modulus 
(Spearman R = 0.84) and also a strong negative correlation between pore diameter 
and Young’s modulus (Spearman R = -0.84), i.e. enlargement of the pore size led to 
a decrease in the stiffness of the composite. The mean values and standard 
deviations were determined from 5 independent experiments (Table I/ 1). 








Young’s moduli of 
elasticity [kPa] 
Col 0.5/HA 30 0.5 30 502±24 1.41±0.76 
Col 0.5/HA 40 0.5 40 468±38 3.10±0.63 
Col 0.5/HA 50 0.5 50 405±74 4.65±1.57 
Col 0.5/HA 60 0.5 60 298±69 5.13±0.23 
Col 0.5/HA 70 0.5 70 205±72 6.09±0.11 
Col 1.0/HA 50 1.0 50 267±74 62.02±23.62 
Col 1.5/HA 50 1.5 50 195±28 168.74±36.94 
Col 2.0/HA 50 2.0 50 108±28 289.98±161.89 
3.1.3. Discussion I 
We have demonstrated in our work the influence of the collagen/HA ratio on cell 
adhesion, proliferation and differentiation, and the mechanical properties of the 
scaffold. The mixtures of 40 and 50% HA with 0.5% collagen (Col0.5/HA40 and 
Col0.5/HA50) were be found the most suitable for cell adhesion, proliferation and 
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differentiation. The explanation for the results seem to lie in the porosity of the 
scaffolds. Pores have been reported to play a key role in bone tissue formation. They 
allow the migration and proliferation of osteoblasts and/or MSCs, and also 
vascularization (Kuboki et al. 1998). The reported minimum pore size is around 100 
μm; however, the recommended diameters are larger than 300 μm (Hulbert et al. 
1970). Dawson and Orefo (2008) prepared composite type I collagen/ HA scaffolds 
from a 1 wt % solution of type I collagen and 70% HA. Their scaffold was suitable for 
proliferation and osteal differentiation of human bone MSCs, and was characterized 
by an average pore size of 135 μm. However, larger pores undisputedly promote 
better adhesion and proliferation of MSCs (Dawson and Oreffo 2008). The optimal 
pore diameter in our study was found to be around 400 μm, and was characteristic of 
the optimal mixture of 40–50% HA with 0.5% collagen (Col0.5/HA40 and 
Col0.5/HA50). This size evidently enables sufficient cell and nutrition diffusion and, 
simultaneously, maintains adequate scaffold solidity and firmness. The effect of pore 
size seems to be crucial, and decreasing the pore diameter below 200 μm resulted in 
dramatically lower proliferation. The main conclusion of this study is that the optimal 
collagen/HA mixture of 40–50% HA with 0.5% collagen (Col0.5/HA40 and 
Col0.5/HA50) was able to induce osteogenic differentiation of MSCs. Naturally, this 
scaffold could be further modified and improved. Modification of the surface charge 
would probably improve cell adhesion and the mechanical properties of the scaffolds. 
However, one of the important findings of this study is our observation that any 
potential scaffold for seeding with MSCs differentiated into osteoblasts has to be 
tested over a longer time scale. Clearly, neither cell adhesion nor data obtained 14 




3.1.4. Conclusion I 
Our study confirmed that a higher collagen content increased scaffold stiffness, but 
that the greater stiffness was not sufficient for bone tissue formation. Bone tissue 
formation is a complex process, evidently also dependent on scaffold porosity. In 
addition, we found that the scaffold pore diameter was dependent on the 
concentration of collagen and HA, and that it could play a key role in cell seeding. 
The suitable pore size for optimal cell proliferation was evaluated to be around 400 
μm. In conclusion, the optimal composite scaffold for new bone formation and cell 





3.2. Experiment II  
Collagen/hydroxyapatite scaffold enriched with polycaprolactone 
nanofibers, thrombocyte-rich solution and mesenchymal stem cells 
promotes regeneration in large bone defect in vivo 
A 3D scaffold Col0.5/HA50 (Coll/HA) prepared in our previous work (Experiment I) 
was enriched with polycaprolactone nanofibres (Coll/HA/PCL), autologous MSCs in 
osteogenic media, and thrombocyte-rich solution (TRS) in this study as an optimal 
implant for bone regeneration in vivo in white rabbits. Nanofibres were used to 
optimize the viscoelastic properties of the Coll/HA scaffold for bone regeneration. 
MSCs and TRS in the composite scaffold were used to promote new bone tissue 
formation. Three types of Coll/HA/PCL scaffold were prepared: an MSCs-enriched 
scaffold, a TRS-enriched scaffold, and a scaffold enriched with both MSCs and TRS. 
These scaffolds were implanted into femoral condyle defects 6 mm in diameter and 
10 mm in depth. Untreated defects were used as a control. Macroscopic and 
histological analyses of the regenerated tissue from all groups were performed 12 
weeks after implantation. 
3.2.1. Methods II 
3.2.1.1. Scaffold composite preparation  
Our previous study describes the preparation of a Coll/HA scaffold without PCL 
nanofibres (Prosecka et al., 2010). Briefly, bovine collagen type I as an 8 wt% 
aqueous solution (VUP, Brno, Czech Republic), HA as a 350 nm nanoparticle powder 
(Research Institute of Inorganic Chemistry, Usti nad Labem, Czech Republic), N-(3-
dimethylamino propyl)-N’-ethylcarbodiimide hydrochloride, and N-hydroxysuccinimide 
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(Sigma Aldrich, Germany) were used as received. A collagen solution (0.5 wt% 
concentration) was mixed with a calculated amount of HA powder to prepare a 50 
wt% mixture of HA powder in a collagen solution. In this study, 0.065 g PCL 
nanofibres (prepared as described below) were added to the Coll/HA mixture (10 x 
10 cm of PCL nanofibres were cut into approximately 2mm pieces and mixed into the 
Coll/HA solution) (Coll/HA/PCL). The homogenized mixture was frozen on 12-hole 
culture plates and lyophilized (-55°C, 15 Pa, 24 h; CHRIST ALPHA 1-4 LSC). 
The lyophilized porous collagen-based scaffolds were cross-linked with an ethanol 
solution containing N-(3-dimethylamino propyl)-N′-ethylcarbodiimide hydrochloride 
and N-hydroxysuccinimide in a molar ratio of 2:1. The samples were then washed in 
a 0.1 M solution of Na2HPO4∙12 H2O and subsequently in distilled water and freeze-
dried at -55°C and 15 Pa for 24 h.  
The morphology of these scaffolds was observed using a scanning electron 
microscope (Philips Quanta 200) (Figure II/ 3). The pore size of the Coll/HA and 
Coll/HA/PCL matrices were characterized using the MATLAB image analysis 
program. Quantitative data are presented as mean ± SD. Average values were 
determined from at least 3 independently prepared samples. 
3.2.1.2. Mechanical testing of the scaffolds 
The initial moduli of elasticity of the Coll/HA and Coll/HA/PCL porous bone scaffolds 
under compression were obtained at room temperature using a traction machine 
(Zwick Roell, Ulm, Germany) equipped with a 1-kN load cell as was already 
mentioned in previous section 3.1.1.8. The loading velocity was 1 mm/min, in 
accordance with the studies of Narbat et al. (2006) and Olah et al. (2006). Statistica 
base 9.1 (StatSoft, Inc., Tulsa, OK, USA) was used for the statistical analysis of the 
58 
 
initial moduli of elasticity. Normality was tested with the Shapiro-Wilk W test. The 
difference in the initial moduli between the Coll/HA and Coll/HA/PCL scaffolds was 
tested with the Mann-Whitney U test. The initial moduli are presented as mean value 
± standard error (Table II/ 2). 
3.2.1.3. Fabrication of PCL nanofibres 
The fabrication of PCL nanofibres has been described in our previous study 
(Jakubova et al. 2011). Briefly, we used an electrospinning method (Sachlos et al. 
2006) or prepared PCL nanofibres from PCL with a molecular weight of 40 000 
(Wako Chemicals GmbH, Neuss, Germany). Electrospinning was performed using 
10% PCL dissolved in chloroform:ethanol (9:1). A high-voltage source generating 
voltages of up to 50 kV was applied to the polymer solution. Electrospun nanofibres 
were deposited on the grounded collecting electrode. The nanofibres were stored in 
a desiccator until use.  
3.2.1.4. Isolation of rabbit autologous MSCs 
Blood marrow aspirates were obteined from the os illium (tuber coxae ala osis illi) of 
anesthetised rabbits (age 3 months) into a 10-mL syringe with 1 mL PBS and 25 IU 
heparin/mL (Zentiva, Czech Republic) connected to a bioptic needle (16 gauge) as 
was already mentioned in previous section 3.1.1.2.  
3.2.1.5. Preparation of TRS 
Preparation of TRS took place through the Hematology Service of the General 
Teaching Hospital, Prague, Czech Republic. PRP (volume, 400 mL; thrombocyte 
concentration, 225 x 109) was centrifuged (2250 x g, 15 min), and the supernatant 
was discarded. The resulting thrombocytes were washed in washing buffer (pH 6.5, 
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113 mM NaCl, 4.3 mM K2HPO4, 4.3 mM Na2HPO4, 24.4 mM NaH2PO4, and 5.5 mM 
glucose), as described by Baenziger et al. (1971). Thrombocyte washing was 
repeated 3 or 4 times. Contaminating leukocytes and erythrocytes were removed 
through further centrifugation (120 x g, 7 min). The thrombocytes were then 
resuspended in 40 mL washing buffer and centrifuged again at 120 x g for 7 min to 
recover those that were sedimented in the first spin. The thrombocytes were pelleted 
via centrifugation (2000 x g, 15 min), washed once, and finally resuspended in buffer 
(109 mM NaCl, 4.3 mM K2HPO4, 16 mM Na2HPO4, 8.3 mM NaH2PO4, and 5.5 mM 
glucose, pH 7.5).  
A TRS concentration of 1.35 x 106/μL was used for each sample. Thrombocytes 
and TRS were manipulated in a sterile tissue culture hood in a clean room. TRS was 
stored in centrifuge tubes in a clean room until use. The temperature in the room was 
set at 22°C.  
3.2.1.6. Preparation of scaffold types 
MSCs-enriched scaffolds 
Scaffolds with a diameter of 10 mm and a height of 20 mm were sterilized using 
plasma sterilization. Two weeks before seeding with MSCs, the scaffolds were de-
aerated and incubated in differentiation medium (MEM with L-glutamine, 10% FBS, 
100 IU/mL penicillin, and 100 μg/mL streptomycin) supplemented with 100 nM 
dexamethasone, 40 μg/mL ascorbic acid-2-phosphate, and 10 nM glycerol 2-
phosphate disodium salt hydrate at 4–8°C for 14 days. One day before surgery, the 
autologous cells in the culture medium were trypsinated, and in a second passage 
were seeded on the scaffolds at a density of 2 x 106/cm2 on a 24-well plate. The 
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differentiation medium was added. The plate was centrifuged at 7x g for 20 min and 
cultured at 37°C in a humidified atmosphere with 5% CO2. 
TRS-enriched scaffolds  
Scaffolds on the 24-well plate were immersed in TRS (1.35 x 106 thrombocytes/μL) 
for 2 h for adhesion. After incubation, the functionalized scaffolds were rinsed twice in 
PBS (pH 7.4). The differentiation medium was added and cultured at 37°C in a 
humidified atmosphere with 5% CO2. 
MSCs- and TRS-enriched scaffolds 
Scaffolds on the 24-well plate were immersed in TRS (1.35 x 106 thrombocytes/μL) 
for 2 h to enable adhesion. After incubation, the functionalized scaffolds were rinsed 
twice in PBS (pH 7.4). Then, the autologous cells were seeded on the scaffolds at a 
density of 2 x 106/cm2 and differentiation medium was added. The plate was 
centrifuged at 7 x g for 20 min and cultured at 37°C in a humidified atmosphere with 
5% CO2. 
3.2.1.7. Surgical procedure and scaffold implantation  
Thirty 3-month-old male New Zealand white rabbits weighing 3.0 ± 0.5 kg were 
obtained from a conventional breeder (BioTest, Czech Republic) and housed in 
standard cages without bedding. The rabbits were fed ad libitum using a standard 
granular mixture for rabbits (TM-MaK 1, Bergman, Czech Republic). The 
maintenance and handling of the experimental animals followed European Union 
Council Directive 86/609 EEC and the Ethical Principles and Guidelines for Scientific 
Experiments on Animals. The study was approved by the expert committee of the 
Institute of Physiology at the Academy of Sciences (Prague, Czech Republic) and 
conformed to Czech Animal Protection Law No. 246/92.  
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The surgical procedure was conducted under general anaesthesia using ketamine 
(35 mg/kg-1) and xylazine (3 mg/kg-1) and subsequent inhalation of O2 + 1.5–2.0% 
halothane during surgery. A critical size defect (Katthagen 1986) was made in the 
femoral condyles using a 3.2-mm drill gradually expanded to obtain a 6-mm defect 
that was 10 ± 0.5 mm in depth (Figure II/1). The defects in 7 rabbits were filled with 
MSCs-enriched scaffolds, 8 rabbits received TRS-enriched scaffolds, and MSCs- and 
TRS-enriched scaffolds were placed in 8 rabbits. The defects were left empty in 7 
rabbits (control group). Before implantation, the scaffolds were sized to fit the defect 
exactly. Wound healing was uncomplicated in all cases throughout the postoperative 
period. Antibiotics (10 mg/kg/day i.m. cefalexin monohydrate ad us. vet.) and 
analgesic (0.1 mg∙kg-1∙day-1 s.c. of butorphanol tartrate ad us. vet.) were 
administered during the first 5 days. The rabbits were not limited in their movement 
after surgery. The rabbits were euthanized 12 weeks later, and their femoral condyles 






Figure II/ 1: Surgical procedure. Critical size defects were made in femoral condyles using 
a 3.2-mm drill gradually expanded to obtain defects 6 mm in diameter and 10 ± 0.5 mm in 
depth.  
3.2.1.8. Histological processing  
All of the fixed samples were demineralised in 12.5% ethylenediaminetetraacetic acid 
solution (Komplexon III, Penta, Prague, Czech Republic) for 3 months and embedded 
in paraffin.  
Qualitative analyses 
Five serial histological sections 5 µm in thickness (between-section distance, 50 µm) 
were processed from each paraffin-embedded tissue block. In a randomly selected 
tissue block, another series of 20 consecutive sections was cut to examine the 
variability among the serial sections. The sections were stained with hematoxylin-
eosin, blue Mallory trichrome, and green trichrome (Kocova 1970). 
Bone quantification 
Four serial histological sections 5 µm in thickness (between-section distance, 50 µm) 
were processed from each paraffin-embedded tissue block. In a randomly selected 
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tissue block, another series of 20 consecutive sections was cut to examine the 
variability among the serial sections. The sections were stained with blue Mallory 
trichrome and green trichrome.  
Four micrographs per tissue block (i.e. 1 micrograph per section) were taken using 
a 2× objective. The image field was broad enough to capture the regenerating bone 
defect, which was centred in the micrographs. Using Ellipse software (Košice, Slovak 
Republic), 3 concentric circles of increasing diameter (2, 4, and 6 cm) were projected 
onto each micrograph. The outer circle delineated the borders of the original 6-cm 
defect (area A) drilled within the femoral condyle. The 3 compartments defined by 
these circles were 2 annuli (A1 was the area between the outer and the inner 
concentric circles; A2 was the area between the inner and the central concentric 
circles) and the area of the central circle (A3). The geometric characteristics of these 
areas are summarised in Table II/ 1, and their positions are illustrated in Figure II/ 2A. 
The outer compartment close to the borders of the original bone defect was 
represented by the area of A1, the inner compartment by the area of A2, and the 
central compartment of the original bone defect by the area of A3.   
Next, a randomly positioned uniform grid of equidistant points was placed on the 
micrographs in an overlay (Figure II/ 2B), so the number of points striking each 
compartment was proportional to its area (see Table II/ 1). In each of the 4 
micrographs per tissue sample, we counted the number of points striking the bone 
tissue within the total area of bone defect A, and also within the individual 
compartments (A1, A2, and A3). The area of bone was calculated by multiplying the 
number of counted points by the area corresponding to each point (Mouton et al. 
2002). The volumes of the corresponding three-dimensional compartments were 
calculated by multiplying the areas by the number and the thickness of the sections 
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(see Table II/ 1). We calculated the volume fraction of each compartment within the 
total examined volume (see Table II/ 1). The bone volume was expressed as the 
volume fraction of bone tissue within the whole defect and within the outer, inner, and 
central compartments. If the bone tissue had regenerated equally within all 3 
compartments (i.e. in the same manner within the whole volume of the defect), the 
volume of bone tissue found within the individual compartments was proportional to 
the volume of these compartments, and we predicted that all 3 compartments would 
harbour the same concentration of bone tissue. 
To test which of the compartments was preferentially occupied by bone tissue, we 
divided the total number of points striking the bone tissue by the volume fraction of 
each compartment within the examined volume of the defect. In this way, we 
calculated the expected number of points (Pexp) striking the bone tissue within each 
volume-occupying compartment, provided that the bone tissue had regenerated 
equally within all 3 compartments. The ratio between the observed number of points 
striking the bone tissue (Pobs) and Pexp was the relative deposition index (RDI = 
Pobs/Pexp), which was used to compare the outer, inner, and central compartments. 
For uniform bone regeneration, RDI was equal to 1, but for preferential bone growth, 
the index was >1. This principle for quantifying the preferential distribution of 
immunogold nanoparticles using electron microscopy has been described and 
thoroughly evaluated by (Mayhew et al. 2002; Mayhew et al. 2009). However, the use 
of RDI is not limited to electron microscopy, because between-compartment 
comparisons and mathematical apparatus are scale independent. 
We then calculated the partial chi-squared values for each pair using the following 
equation: (Pobs – Pexp)
2/Pexp. The total chi-squared values were compared with the 
chi-squared distribution to test the null hypothesis stating that the distribution pattern 
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among the compartments was random. Our study had 2 degrees of freedom (Table 
II/ 3). Estimates of bone volume were based on 4 tissue sections per tissue block 
sampled from the approximate middle of the bone defect. However, the bone content 
might have differed among the histological sections. We therefore assessed the bone 
area in a series of 20 equidistant sections in a randomly selected tissue sample. The 
variation in the bone area quantified in the serial sections was estimated using the 
error coefficient calculated with the quadratic approximation formula of Matheron, 
which was modified for use in a stereological context (Gundersen and Jensen 1987). 
The resulting value was <0.1, which quantified the sampling error in our study (Figure 
II/ 2C). 
The data was processed with Statistica Base 9.1 (StatSoft, Inc., Tulsa, OK, USA). 
The tests on the randomness of the bone distribution among compartments was 
based on a chi-squared distribution. The Man-Whitney U test was used to test the 
equality of population medians among the groups under study. All results were 
considered statistically significant if p was <0.05. 
 
Table II/ 1. Outer, inner, and central compartments of bone defects under examination.  
 Compartment 
Parameter Outer Inner Central 
Circle diameter (mm) 6 4 2 
Area per section (mm
2
) 15.71 9.42 3.14 
Area label A1 A2 A3 
Volume in 4 sections (mm
3
) 3.142 1.884 0.628 











Figure II/ 2: Histological assessment of 
bone quantity and distribution. (A) The 
total area of bone defect A on the 
histological sections was divided with 3 
concentric circles (radius r1 = 3 cm, r2 = 2 
cm, and r3 = 1 cm) into 3 arbitrary 
compartments. The outer compartment (dark 
grey) was designated A1, the inner 
compartment (light grey) was A2, and the 
central compartment (white) was A3. (B) A 
stereological point grid was superimposed 
on the histological micrographs, and the 
points striking the bone tissue within the total 
area of the bone defect were counted. (C) 
The area of bone (estA) estimated with a 
stereological point grid varied within the 
series of adjacent histological sections 
(green dashed line, left y-axis), thus 
affecting the moving average (blue dotted 
line, left y-axis). The coefficient of error 
(estCE), which was estimated according to 
the method of Gundersen and Jensen 
(1987), decreased as the number of serial 
sections included in the study increased (red 
line, right y-axis), thus illustrating the effect 
of histological sampling on the resulting 
data. This graph demonstrates that taking 4 
sections for quantification reduced the 
sampling error to an acceptable value of 
<0.1. 
affecting the moving average (blue dotted line, left y-axis). The coefficient of error 
(estCE), which was estimated according to the method of (Gundersen and Jensen 1987), 
decreased as the number of serial sections included in the study increased (red line, right 
y-axis), thus illustrating the effect of histological sampling on the resulting data. This 
graph demonstrates that taking 4 sections for quantification reduced the sa pling error to 
an acceptable value of <0.1. 
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3.2.2. Results II 
3.2.2.1. Morphological characterization of scaffolds 
The morphology of these scaffolds was observed using a scanning electron 
microscope (Philips Quanta 200) (Figure II/ 3). 
 
 
Figure II/ 3: Morphology of a collagen and HA (Coll/HA) scaffold enriched with 
polycaprolactone nanofibres (Coll/HA/PCL). The scaffold morphology was analysed using 




3.2.2.2. Characterization and mechanical testing of scaffolds 
The pore size of the scaffolds was observed using scanning electron microscopy and 
the MATLAB image analysis program. The initial moduli of elasticity under 
compression for the Coll/HA/PCL scaffolds were higher than the moduli of the 
Coll/HA scaffolds (Table II/ 2).  
Mechanical testing of scaffolds: Our results clearly proved that the presence of PCL 
nanofibre at a low concentration was sufficient to stiffen the collagen scaffold. The 
initial modulus of elasticity under compression was higher for the Coll/HA/PCL 
scaffolds namely 8.5 ± 3.3 kPa than for the collagen/HA scaffolds (3.5 ± 0.4 kPa). 
The goal of our in vivo study and histology analysis was to determine whether such 
scaffold strengthening is optimal for bone regeneration (Table II/ 2).  
 
Table II/ 2: Characterization and mechanical testing of a collagen and HA (Coll/HA) 















Coll/HA 0.5 50 402 ± 52 0 3.5 ± 0.4 




3.2.2.4. Macroscopic evaluation 
A macroscopic evaluation of samples from all groups was made after the joint 
capsule in the articular cavity had been removed to obtain a small amount of synovial 
fluid. The joint capsule and the articular surface showed no signs of inflammation in 
any of the groups (Figure II/ 4). 
 
Figure II/ 4: Macroscopic evaluation.  The defects in rabbits in the groups treated with 
MSCs-enriched (A), TRS-enriched (B), and MSCs- and TRS-enriched (C) scaffolds were 
completely healed. The same result was observed in the control group (D), but the 
localization of the defect revealed deformation of the condyles. 
3.2.2.3. Histological evaluation 
Qualitative analyses 
Qualitative histological analysis revealed the formation of new bone trabecules in the 
enriched scaffold groups but not in the control group, which had no scaffolds (Figure 




Figure II/ 5: Histology of the healing bone defects with implanted MSCs- and TRS-
enriched scaffolds (A-C) compared with the defects in the control group (D-F). (A) 
Newly formed bone trabecules were found growing from the periphery of the healing bone 
defect toward its centre. Eosinophilic remnants of bone scaffolds were partially incorporated 
into the bone trabecules. The space among the trabecules was filled with granulation 
connective tissue and adipose tissue. (B, C) Newly formed bone (stained green) contained 
partially resorbed scaffold trabecules (stained reddish). In some parts of the bone, the 
lamellae formed concentric layers with embedded osteocytes. Most of the surface of the 
bone was covered with osteoblasts. (D) Bone trabecules were found predominantly at the 
periphery of the healing defects. (E, F) Central parts of the healing defects were often 
occupied by bone marrow and adipose tissue without any signs of bone formation. 
Hematoxylin-eosin (A, E), green trichrome (B, C, F), and Mallory blue trichrome (D) staining.  
Bone quantification 
With the exception of the samples with scaffolds enriched with both TRS and MSCs, 
the distribution of the bone tissue was not random, and the null hypothesis of no 
difference in bone deposition among the compartments was rejected (p < 0.001; see 
Table II/ 3). The use of scaffolds enriched with MSCs, scaffolds enriched with TRS, 
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or no scaffolds resulted in preferential bone deposition in the outer compartment of 
the experimental defect (RDI > 1). Only samples containing bone scaffolds enriched 
with both MSCs and TRS showed uniform bone deposition in all 3 compartments.  
The intersections represent the numbers of points of a stereological grid striking 
the bone tissue. The relative deposition index (RDI) was calculated as the ratio 
between observed intersections (Pobs) and expected intersections (Pexp), according to 
the volume fraction of each compartment within the bone defect. Partial chi-squared 
values were summed to the total chi-squared value, which was tested against the chi-
squared distribution for degrees of freedom = (3-1) rows*(2-1) columns = 2. In the 
TRS-enriched scaffold, MSCs and TRS-enriched scaffold, in MSC-enriched scaffold 
samples and in samples without scaffolds, total the chi-squared value was p < 0.001. 
With the exception of the distribution in the MSC- and TRS-enriched scaffold 
samples, the distribution of bone tissue was nonrandom, and bone was deposited 
preferentially in the outer compartment (RDI > 1). The proportion of the partial chi-
squared value is given in the last column for the compartments in groups with 




Table II/ 3: Distribution of bone tissue within individual volume compartments in the 































































































Outer 1558 1447.78 1.08 8.39 33.32 
Middle 823 868.67 0.95 2.40   
Central 225 289.56 0.78 14.39   
Column totals 2606 2606 1 
25.18 
p < 0.001   




Outer 2128 2093.33 1.02 0.57 
 
Middle 1212 1256.00 0.96 1.54 
  
Central 428 418.67 1.02 0.21 
  
Column totals 3768 3768 1 2.32 
  
MSCs-enriched scaffold compartment 
 
Outer 1491 1197.22 1.25 72.09 43.65 
Middle 521 718.33 0.73 54.21   
Central 143 239.44 0.60 38.85   
Column totals 2155 2155 1 
165.14 
p < 0.001   
      
No scaffold compartment     
Outer 444 338.89 1.31 32.60 44.20 
Middle 129 203.33 0.63 27.17   
Central 37 67.78 0.55 13.98   
Column totals 610 610 1 73.75 p < 0.001   
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The highest bone volume fraction within the healing defect was found in the 
samples with scaffolds enriched with both MSCs and TRS. The bone volume fraction 
was comparable between the samples with TRS-enriched scaffolds and MSCs-
enriched scaffolds, and the samples without scaffolds contained the lowest bone 
volume fraction (Figure II/ 6A). A comparison of individual compartments revealed 
that the bone volume fraction was highest in the samples with scaffolds enriched with 
both MSCs and TRS. The variability of the bone volume fraction increased from the 







Figure II/ 6: Between-group comparison of bone volume. Bone quantity was expressed 
as volume fraction (Vv) of the bone tissue within the whole reference volume of the defect (A) 
or within the outer (B), inner (C), and central (D) compartments. Data is presented as 
medians. The boxes span the limits of the first and third quartiles, and the whiskers show the 
non-outlier range for each group. The differences were considered statistically significant as 
follows: *p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-Whitney U test, only significant results 
are presented here).  
Whereas  Figure II/ 7 demonstrates examples of good and poor bone regeneration 
at low magnification in the whole defect (see Figure II/ 7 A, B) and also in the outer, 





Figure II/ 7: Histology of healing bone defects. (A) In most samples with scaffolds 
enriched with both TRS and MSCs, bone formation was visible within the whole volume of 
the healing defect. (B) In some bone defects with MSCs-enriched scaffolds, the centre of the 
bone defect lacked newly formed bone trabecules. (C) In most samples of the outer 
compartment, advanced bone formation was found with all scaffold types. Remnants of the 
scaffolds (yellow arrow) were well integrated with thick bone trabecules. (D,E) The inner (D) 
and central (E) compartments of samples treated with scaffolds enriched with both TRS and 
MSCs contained growing bone trabecules covered with osteoblasts (orange [D] and black [E] 
arrows). (F) Several samples with MSCs-enriched scaffolds lacked bone within the central 
compartment, and the scaffold remnants (red arrow) were surrounded by connective tissue. 
Green trichrome (B-D, F) and Mallory stain (A, E). Scale bars: 1 mm (A, B), 100 µm (C-F). 
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3.2.3. Discussion II 
Nanofibers optimized the viscoelastic properties of the Coll/HA scaffold for bone 
regeneration. The correlation between scaffold stiffness and cell behavior is a key 
factor in the fabrication of scaffolds for tissue engineering (Hutmacher 2000; 
Karageorgiou and Kaplan 2005). Scaffold stiffness influences the migration and 
differentiation of MSCs (Reilly and Engler 2010). Our study is in accordance with 
several studies which have reported that fibers can improve scaffold mechanical 
properties (Albanna et al. 2012; Chen et al. 2013). Clearly, the moduli of elasticity 
under compressive testing increased significantly when PCL nanofibers were added 
to the Coll/HA scaffold.  
Moreover, recent studies have shown that there is promising potential for drug 
delivery from nanofibers embedded in a composite foam or gel. In an analogous 
study focusing on chondral regeneration, we showed that the addition of PVA 
nanofibers with adsorbed growth factors simultaneously improved the biomechanical 
properties and cell proliferation on scaffolds in cartilage regeneration (Filova et al. 
2013).  
Our data showed clearly that bone healing throughout the defects was promoted 
when our novel Coll/HA/ PCL composite scaffold enriched with TRS and seeded with 
MSCs was applied. This result is in accordance with several previous clinical and 
animal studies, which have proved that a combination of PRP and autogenous bone 
grafting can improve osteogenesis and enhance bone formation (Kitoh et al. 2004; 
Martins et al. 2010). 
However, PRP has several shortcomings. The first concerns standardization of the 
preparation process, i.e. whether to apply a simple and cheap two-step centrifugation 
method or to use plasmaphaeresis. While the definition of the parameters for the 
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centrifugation method seems to be empirical, for plasmaphaeresis we can clarify the 
content of the product, although the procedure is much more expensive and is 
uncomfortable for patients. (Prosecká et al., 2014). Another much discussed topic 
concerns the PRP content, i. e. the presence of leucocytes and fibrin. Whereas 
leucocytes influence cell proliferation, differentiation, immunity and infection, fibrin 
changes the biomechanical properties (Dohan Ehrenfest et al. 2009). Promotion of 
bone regeneration in rabbits, even with the use of human TRS was shown in our 
study. This outcome clearly suggests a minimal immunological negative response, 
and favors TRS for further preclinical and clinical studies. The application of TRS is 
also more reproducible than the use of autologous PRP from whole blood. Also, 
several studies have discussed and compare the effect of synthetic growth factors 
and PRP. Calori et al. (2008) compared the efficacy of recombinant BMP-7 and PRP 
as bone promoting agents. They support the view that the application of recombinant 
BMP-7 as a bone-stimulating agent is superior to the application of PRP in terms of 
clinical and radiological efficiency in the treatment of persistent long bone non-
unions. 
Many problems remain to be solved, e.g. an effective PRP concentration, donor-
based changes, the presence or absence leucocytes or other activators, and 
differences in scaffold structure. These parameters, and also the time-dependent 
release of growth factors, may influence bone formation. The relationship between 
platelet concentration and growth factor liberation seems to provide a key to bone 
regeneration, but its mechanism is still unclear (Dohan Ehrenfest et al. 2009). The 
effect of various PRP concentrations on tissue healing was reviewed by Wasterlain et 
al. (2012). They described a positive effect of a low PRP number (2 million 
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platelets/μL) on the promotion of anastomotic wound healing, whereas a higher 
amount (5 million platelets/μL) inhibited healing (Wasterlain et al. 2012). 
In our study, we used a TRS concentration of 1.35 x 106 thrombocytes/μL, in 
accordance with the definition of PRP as a minimum of 1 x 106 platelets/μL 
suspended in plasma (Dohan Ehrenfest 2009; Kitoh et al. 2004; Wasterlain et al. 
2012)  and 2-h incubation with our composite Coll/HA/PCL scaffold. This TRS 
concentration promotes bone regeneration and is one of the main outputs of this 
study (Prosecka et al.  2014). 
Moreover, calcium ions contained in biomaterials based on bone cement likely 
work as thrombocyte activators.This is an important consideration in the use of PRP 
in bone regeneration (Chen et al. 2012; Kasten et al. 2008). 
3.2.4. Conclusion II 
The highest volume and the most uniform distribution of newly-formed bone while 
scaffold biodegradation was gradually taking place was found in defects treated with 
scaffolds enriched with both MSCs and TRS. There were lower values in defects 
treated with scaffolds enriched by either component alone. The modulus of elasticity 
in compressive testing was significantly higher in the Coll/HA/PCL scaffold than in the 
scaffold without nanofibres. The composite collagen/HA scaffold functionalized with 
PCL nanofibres and enriched with MSCs and TRS offers a novel, promising 




3.3. Experiment III  
Thin-layer hydroxyapatite deposition on a nanofiber surface 
stimulates Mesenchymal stem cell proliferation and their 
differentiation into osteoblasts 
The aim of the study was to introduce a modern system which will serve as a source 
of bioactive molecules suitable for regenerating bone defects. The system is based 
on MSCs and functionalized nanofibers. The nanofibers can be modified on their 
surface and also enriched in their core with various drugs that could be released 
slowly over the course of days or weeks.  
Pulsed laser deposition was shown to be a suitable method for HA coating of 
coaxial poly-ε-caprolactone/polyvinylalcohol (PCL/PVA) nanofibers. Thin layers 200, 
400, or 800 nm in thickness were deposited onto the nanofiber surface. HA 
deposition clearly modified the nanofiber surface and significantly influenced the 
surface properties. 
3.3.1. Methods III 
3.3.1.1. Coaxial electrospinning of PCL/PVA nanofibers  
A 14% (w/v) PCL solution was prepared as the shell solution by dissolving 7 g PCL in 
50mL chloroform/ethanol (8 : 2) and Journal of Biomedicine and Biotechnology 3 
stirring at room temperature. The core solution consisted of 5% PVA (v/v). The 
coaxial spinneret apparatus consisted of two needles placed together coaxially 
(Lukáš et al. 2009). Two syringe pumps were used to deliver the core solution and 
the shell solution. A high-voltage power supply was used to generate voltages of up 
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to 60 kV, and a span bond was used as the receiving plate to collect the electrospun 
nanofibers. The distance between the tip of the syringe needle and the collecting 
plate was 12 cm. All electrospinning processes were performed at room temperature 
with 56% humidity. In the release study, the core solution consisted of FITC-dextran  
(2 mg/mL, 10,000 MW) dissolved in 1%, 3%, or 5% (v/v) PVA. The process was 
performed on the apparatus described above at room temperature with 52% 
humidity. 
3.3.1.2. HA coatings of nanofibers  
The prepared nanofibers were coated by HA layers of various thicknesses. HA 
[Ca10(PO4)6(OH)2] films were formed by a KrF epimer laser (COMPexPro 205 F) with 
248 nm wavelength, frequency 10 Hz, and energy 600 mJ. The energy density of the 
laser beam was 2 Jcm−2. The deposition proceeded in an H2O + Ar atmosphere at a 
pressure of 40 Pa. The substrate was fixed at a distance of 5 cm from the target HA 
material (cake of pressed powder). The substrate was at room temperature. HA films 
of 200 (PCL/PVA200HA), 400 (PCL/PVA400HA), and 800 nm thickness 
(PCL/PVA800HA) were grown. Pure PCL/PVA core-shell nanofibers were used as a 
control (PCL/ PVA). 
3.3.1.3. Characterization of the scaffolds  
The prepared nanofibrous scaffolds were characterized by scanning electron 
microscopy. Air-dried samples of electrospun HA-coated nanofibers were mounted 
on aluminum stubs and sputter-coated with a layer of gold approximately 60 nm in 
thickness using a Polaron sputter coater (SC510, Polaron, now QuorumTechnologies 
Ltd.) The samples were examined in an Aquasem (Tescan) scanning electron 
microscope in the secondary electron mode at 15 kV (Figure III/ 1 a, b, c, d). 
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3.3.1.4. Mechanical characterization of the scaffolds 
The Young’s moduli of elasticity, the ultimate stresses and the ultimate strains of the 
scaffolds were obtained at room temperature using a Zwick/Roell traction machine 
equipped with a 1 kN load cell. Due to difficulty in producing a layer of PCL/PVA 
nanofibers of uniform thickness, only the samples with the same thickness of the 
basic layer of PCL/PVA nanofibers of pure samples and also with the layer of HA 
were used for mechanical testing. The samples without a layer of HA were therefore 
marked as type I (n = 4), and the samples with the HA layer were marked as type II 
(n = 7). The samples themselves were thin strips of the nanofibers. The initial length 
of all samples was 10 mm. All samples were 10 mm in width. The individual samples 
were about 60 μm in thickness. The samples were prepared in accordance with 
Narbath et al. (2006) and Olah et al. (2006).The template of paper 20 x 50 mm 
(height x width) with a centered rectangular hole 10 x 40 mm was cut, and lines 
marking sample strips 10 mm in width were drawn on its top and bottom stripes. 
Then it was glued to the sheet of composite, and two other strips of paper 5 x 50 mm 
were glued to the back faces of the top and bottom stripes. The individual scaffolds 
were then cut, resulting in four 20 x 10 mm strips consisting of a 10 x 10 mm sample 
between two 5 x 10 mm strips of paper. A tensile test with a loading velocity of 10 
mm/min was applied to the samples. The load was applied until the scaffold ruptured. 
The Young’s moduli of elasticity were determined using linear regression of the 
stress-strain curves at a strain of approximately 1–6% (linear region depending on 
the shape of the curve). The ultimate stress and the ultimate strain were determined 
at the start of the rupture. The stress was defined as the force divided by the initial 
area, and the strain was defined as the elongation of the specimen divided by its 
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initial length. Our own software written in Python programming language was used 
for the evaluation (Figure III/ 2). 
3.3.1.5. Isolation and cultivation of MSCs  
Blood marrow aspirates were obtained from the os ilium (tuber coxae Ala ossis iili) of 
anesthetized miniature pigs (age 6–12 months) as was already mentioned in 
previous section 3.1.1.2.  
3.3.1.6. Seeding MSCs on the scaffolds  
The scaffolds were cut into a round shape with a diameter of 6mm and were 
sterilized using ethylene oxide. Cells were seeded on the scaffolds at a density of 70 
× 103/cm2 in a 96-well plate. Scaffolds with seeded MSCs were cultivated in 
differentiation media: MEM supplemented with 10% FBS, penicillin/streptomycin (100 
IU/ mL and 100 μg/mL, resp.), 100nM dexamethasone, 40 μg/ mL ascorbic acid-2-
phosphate and 10nM glycerol 2-phosphate disodium salt hydrate. The medium was 
changed every 3 days. 
3.3.1.7. Cell viability analysis by the MTT test  
50 μL of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT), and 
1mg/mL in PBS (pH 7.4) were added to 150 μL of sample medium and incubated for 
4 hours at 37°C as was already mentioned in previous section 3.1.1.4. The results 
were examined by spectrophotometry in an ELISA reader at 570 nm (reference 
wavelength 690 nm) (Figure III/ 3). 
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3.3.1.8. Cell viability analysis by the Live/dead staining 
Live/dead staining (BCECF-AM/propidium iodide) and visualization using confocal 
microscopy were performed to determine cell viability as was already mentioned in 
previous section 3.1.1.5. Zeiss LSM 5 DUO confocal microscope (wavelengths: 
BCECF-AM λex = 488 nm and λem = 505– 535 nm; propidium iodide λex = 543 nm and 
λem = 630– 700 nm) (Figure III/ 1 e, f, g, h). 
3.3.1.9. Cell proliferation analysis by the PicoGreen  
The PicoGreen assay was carried out using the Invitrogen PicoGreen assay kit 
(Invitrogen Ltd., Paisley, UK). The proliferation of MSCs on the scaffolds was tested 
on days 1, 7, and 14. The material for an analysis of the DNA content, 250 μL of cell 
lysis solution (0.2% v/v Triton X-100, 10mM Tris (pH 7.0), 1mM EDTA), was added to 
each well containing a scaffold sample. To prepare the cell lysate, the samples were 
processed through a total of three freeze/thaw cycles. A scaffold sample was first 
frozen at −70°C and then thawed at room temperature. Between each freeze/thaw 
cycle, the scaffolds were roughly vortexed. The prepared samples were stored at 
−70°C until analysis. To quantify the cell number on the scaffolds, a cell-based 
standard curve was prepared using samples with known cell numbers (range 100–
106 cells). The DNA content was determined by mixing 100 μL of PicoGreen reagent 
and 100 μL of the DNA sample. The samples were loaded in triplicate, and the 
florescence intensity was measured on a multiplate fluorescence reader (Synergy 
HT, λex = 480–500 nm, λem = 520– 540 nm). The measured data was used to derive 
the absorbance values measured by the MTT assay to the cell counts on the 
scaffolds (Figure III/ 3).  
84 
 
3.3.1.10. Quantitative real-time PCR Analysis  
Total RNA was extracted using an RNeasy Mini Kit according to the manufacturer’s 
protocol. Total RNA was stored at –20°C. The cDNA from 1 μg of total RNA was 
used as a template. cDNA synthesis was performed by a standard procedure 
described in our previous work (Tvrdik et al. 2005). BS and OC mRNA expression 
levels were quantified by means of a LightCycler 480 (Roche Diagnostics, 
Mannheim, Germany) using the double-strand specific dye SYBR Green I according 
to the manufacturer’s protocol. The following primers were used: BS, sense 5-CGA 
CCA AGA GAG TGT CAC-3, antisense 5-GCC CAT TTC TTG TAG AAG C-3 (498 
bp); OC, sense 5-TCA ACC CCG ACT GCG ACG AG-3, antisense 5-TTG GAG CAG 
CTG GGA TGA TGG-3  (204 bp) and beta-actin, sense 5-AGG CCA ACC GCG AGA 
AGA TGA CC-3, antisense 5-GAA GTC CAG GGC GAC GTA GCA C-3 (332 bp) as 
was already mentioned in previous section  3.1.1.7. (Figure III/ 4). 
3.3.1.11. Measurement of the FITC-Dextran release profile 
In order to study the release profile of FITC-dextran, core-shell nanofiber meshes 
with 1% PVA, 3% PVA, or 5% PVA were cut into round patches and incubated with 
1mL of TBS buffer at room temperature. At specific intervals, the TBS buffer was 
withdrawn and replaced with a fresh buffer. The time interval was determined 
keeping in mind the balance between the release of a detectable amount of FITC-
dextran and maintenance of the sink condition. Drug release was quantified using 
fluorescence spectroscopy. Briefly, 200 μL of samples and blank samples were 
measured on a multiplet fluorescence reader (Synergy HT, λex = 480–500 nm, λem = 
520–540 nm) and background subtraction was performed. The cumulative release 
profile of FITC-dextran was obtained, and the half time of release was determined as 
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the time at which the initial fluorescence intensity I0 decreased to I = I0 x e
−1 (Figure 
III/ 5). 
3.3.1.12. Statistical analysis  
Quantitative data are presented as mean SD. For the in vitro tests, average values 
were determined from at least three independently prepared samples. The results 
were evaluated statistically using one-way analysis of variance (ANOVA) and the 
Student-Newman-Keuls Method and the Shapiro-Wilk W test was used to determine 
the normality of the Young’s moduli of elasticity, the ultimate strains and the ultimate 
stresses. The t-test was used to determine the differences between values. The 
Student t-test was used to evaluate the statistical significance of the results of 
quantitative real-time PCR analysis. Differences with P values <0.05 were considered 
significant. 
3.3.2. Results III 
3.3.2.1. Visualization of scaffolds 
Scanning electron microscopy revealed the fibrous morphology of the PCL/PVA 
nanofibers (Figure III/ 1a). Pulsed laser deposition of an HA layer 200 nm in 
thickness did not affect the fibrous morphology or the porosity of the nanofibers 
(Figure III/ 1b). However, the fibrous character of the samples with an HA layer 400 
nm in thickness (Figure III/ 1c) was less well preserved, and the porosity of the 
scaffold decreased. The fibrous morphology disappeared completely in samples with 





Figure III/ 1: Visualization of scaffolds by SEM and confocal microscopy. The prepared 
scaffolds were visualized using SEM (a, b, c, d). On day 7, MSCs were stained using 
BCECF-AM and propidium iodide for live/dead staining and the samples were visualized by 
confocal microscopy (e, f, g, h); PCL/PVA (a, e), PCL/PVA200HA (b, f), PCL/PVA400HA (c, 
g) and PCL/PVA800HA (d, h). 
3.3.2.2. Mechanical characterization of the scaffolds 
There is a significant difference in the moduli of elasticity between these groups 
(determined by the T-test; p = 0.04) (Figure III/ 2a) and also in the ultimate strain 
(p<0.001) (Figure III/ 2b), but not in the ultimate stress (p = 0.26) (Figure III/ 2c). We 
found significant differences in Young’s moduli of elasticity between samples without 
an HA layer and those with an HA layer (P = 0.04). The Young’s modulus of elasticity 
in the case of pure PCL/PVA nanofibers was 1.76 ± 0.50 Mpa, while the modulus for 
the samples with an HA layer was 5.40 ± 3.09 MPa; the difference was significant 
(see Figure III/ 2a). Significant differences between these two groups were also found 
in the case of ultimate strains (P < 0.001). Here, the value obtained for pure 
PCL/PVA scaffolds was 0.23 ± 0.03, while for scaffolds with an HA layer the value 
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was 0.09 ± 0.04, (see Figure III/ 2b). No significant differences were found when 
analyzing the ultimate stresses (P = 0.26), although the value for the group with an 
HA layer, 0.36 ± 0.27 MPa, was higher than the value for the pure PCL/PVA 








Figure III/ 2: The moduli of elasticity, the ultimate strain and ultimate stress of the 
group of the pure PCL/PVA composite (type I) and the group of the PCL/PVA 




3.3.2.3. Cell metabolic activity and viability 
The metabolic activity of viable MSCs was detected by MTT assay on day 1, 7, and 
14 (Figure III/ 3). 
 
Figure III/ 3: Cell metabolic activity and viability. Results of the MTT assay for PCL/PVA, 
PCL/PVA200HA, PCL/PVA400HA, PCL/PVA800HA samples (a).  Cell viability calculated as 
derivation of absorbance values from the MTT assay to the cell counts determined by Pico 
Green assay (b).  (Mean ± SD). Statistical significant differences between scaffolds were 
observed by MTT test on day 14:  PCL/PVA800HA> PCL/PVA, PCL/PVA200HA; 
PCL/PVA400HA> PCL/PVA, PCL/PVA200HA.The significant differences between scaffolds 
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were also  found on day 14 after MTT/Pico Green results derivation: PCL/PVA400HA> 
PCL/PVA, PCL/PVA200HA, PCL/PVA800HA; PCL/PVA800HA> PCL/PVA, PCL/PVA200HA. 
3.3.2.4. Expression of bone tissue markers 
Osteogenic differentiation of MSCs was detected by real-time PCR analysis of OC 
and BS expression on day 7 and 14. Interestingly, the samples with an HA coating 
800 nm in thickness were characterized by a significantly higher expression of BS 
and OC genes than the pure PCL/PVA samples (Figure III/ 4). 
 
Figure III/ 4: Expression of bone tissue markers. The expression levels of BS and OC 
mRNAs, osteogenic markers, were detected on day 7 and 14 for all samples. (Mean ± SD).  
Expression of Osteocalcin 
Expression of Bone Sialoprotein 
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3.3.2.5. Time-dependent release profile of coaxial PCL/PVA nanofibers 
The release of FITC-dextran from samples with a different content of PVA core was 
analyzed using fluorescence spectroscopy. Samples were analyzed for 240 h, 
supernatants were collected at intervals of 24 h. The half-time of release from coaxial 
nanofibers was strongly dependent on the presence of a hydrophilic core polymer 










































Time depend release profile of coaxial PCL/PVA nanofibers
PCL/1% PVA PCL/3% PVA PCL/ 5% PVA
 
Figure III/ 5: Time-dependent release profile of coaxial PCL/PVA nanofibers. Core/shell 
nanofibers containing FITC-dextran dissolved in 1% PVA showed the highest burst release 
(79% of FITC-dextran released in 24 h). The half time of release was calculated as τr = 18 h. 
The release of FITC/dextran from fibers with 3% PVA showed a slower release; however, an 
intense burst release was observed (65% of FITC-dextran released in 24 h). The half-time of 
release was prolonged to 24 h. Interestingly, samples with 5% PVA as the core polymer 
showed the most sustained release profile. The burst release was reduced to 52% of FITC-
dextran release in 24 h, and the half-time of release was shifted to 54 h. The results show 
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clearly that different concentrations of the water-soluble core significantly affect the release 
profiles of incorporated substances. (Mean ± SD).  
3.3.3. Discussion III 
Coaxial core-shell nanofibers were prepared from PCL as a shell material and PVA 
as a core material. PCL has good biocompatibility and enables the successful 
cultivation of MSCs (Jakubova et al. 2011) and osteogenic cells (Rampichova et al. 
2013). However, PVA is a water-soluble material and has been employed as a 
suitable substance for the delivery of bioactive compounds from the nanofiber core 
(Buzgo et al. 2013). To improve the surface parameters for MSCs seeding, coaxial 
nanofibers were further functionalized by pulsed laser deposition of HA. Thin layers 
200, 400, or 800 nm in thickness were deposited onto the nanofiber surface. HA 
deposition clearly modified the nanofiber surface and significantly influenced the 
surface properties. Scanning electron microscopy revealed the fibrous morphology of 
PCL nanofibers (Figure III/ 1a). Pulsed laser deposition of an HA layer 200 nm in 
thickness did not affect the fibrous morphology or the porosity of the nanofibers 
(Figure III/ 1b). However, the fibrous character of samples with an HA layer 400 nm in 
thickness (Figure III/ 1c) was less well preserved, and the porosity of the scaffold 
decreased. The fibrous morphology disappeared completely in samples with an HA 
coating 800 nm in thickness (Figure III/ 1d). 
The proliferation and the differentiation of MSCs on HA coated scaffolds are 
separate processes. Our HA-coated nanofiber scaffolds clearly displayed a positive 
effect on the differentiation of MSCs into osteogenic cells, but not on cell proliferation.  
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On the basis of these results, the HA layer 800 nm in thickness has been 
demonstrated to be optimal for osteogenic differentiation of cells and for bone tissue 
engineering applications. 
3.3.4. Conclusion III 
The more positive effect of HA coated nanofiber scaffolds on cell proliferation 
observed in our study could be improved. Core/shell nanofibers offer a promising 
new approach as a system for delivering bioactive molecules directly into a tissue 
defect site. Proliferation and stimulating factors can be encapsulated into the core of 
the nanofibers. The encapsulation of bioactive agents inside the nanofibers can 
increase their ability to stimulate proliferation and thus further improve the positive 
effect of nanofiber scaffolds on MSCs proliferation and differentiation. HA coated 
coaxial PCL/PVA nanofibers seems to be a promising novel drug delivery system 
suitable for bone tissue engineering. 
In addition, the biomechanical properties were improved after HA deposition on 
PCL/PVA nanofibers, as the value of the Young’s modulus of elasticity increased 





The causes of large bone defects include tumours, infectious diseases and traumas. 
There is a medical need for bone regeneration as a way to treat these defects. It is 
well known nowadays that the successful treatment of bone loss requires a 
combination of an osteoinductive signal, an osteoconductive matrix, and cell 
response to the osteogenic potential (Bose et al. 2012; Cancedda 2003). 
Therefore, there is a major clinical need to promote the development of strategies 
to replace diseased bone tissue with a graft capable of integrating with the 
surrounding healthy tissue (Kitoh et al. 2004). 
Many materials have been reported to fulfil these requirements, including 
natural/synthetic polymers, metals and ceramics (Cancedda 2003; Liu et al. 2007). 
Many of them, e.g. HA and collagen, are known as osteoinductive and 
osteoconductive materials and they enhance osteogenic differentiation when seeded 
with MSCs (Heino et al. 2004; Kraus and Kirker-Head 2006; Mao et al. 2005; Marks 
and Odgren 2002). 
The current standard in tissue engineering is to combine cells, especially 
autologous cells, and osteoconductive scaffolds, which can be functionalized with 
growth factors, preferentially serving as a controlled delivery device (Bose et al. 
2012).  
On the basis of a study of current literature, we prepared a promising new smart 
scaffold with potential for clinical use. We found an optimal ratio of biocompatible, 
biodegradable, osteoconductive and also osteoinductive materials for a 3D scaffold 
with optimal pores for cell ingrowth and vascularization (Prosecka et al. 2014). During 
our in vitro and in vivo studies, we found that a 0.5% Type I collagen and 50% of HA 
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(1:1 wt%) 3D scaffold with pore size around 400 um is the most suitable for cell 
proliferation, viability and differentiation of MSCs differentiated into osteoblasts, while 
the mechanical properties were still good (Prosecka et al. 2011). However, we also 
wanted to improve the mechanical properties of the scaffold, and make it more 
suitable for in vivo testing. We found that PCL nanofibers mixed into the 3D Coll/HA 
scaffold significantly improved the mechanical properties of the scaffold. We also 
wanted to know the effect of PRP on accelerating bone healing. We found in the in 
vivo study, that Coll/HA scaffolds enriched with MSCs or with TRS, or with both 
MSCs and TRS, promoted much better formation of new bone tissue throughout the 
defect than when the defect was left to heal without treatment. However, the scaffold 
enriched with both MSCs and TRS supported the best formation of new bone tissue 
and also the most uniform distribution of newly-formed bone (Prosecka et al. 2014).  
We went on to investigate a fabrication process, and we prepared a scaffold from 
materials that meet the European Medicines Agency requirements and can be 
developed for human applications.  
We also found pulsed laser deposition, a suitable method for modifying the surface 
of high temperature sensitive materials, and a suitable thickness (800 nm) of the HA 
layer for MSCs differentiation (Prosecka et al. 2012).  
However, one of the most discussed issues in the area of tissue engineering is the 
ability to generate appropriate numbers of cells when too many cells can be just as 
detrimental as too few, and the capacity for those cells to differentiate from, and 
maintain, the correct phenothype and perform specific biological functions. Other 
issues are invasivity and site morbidity due to cell harvesting, in vitro cultivation, 




It is nowadays increasingly accepted that there is a “wound healing cascade” 
thanks to which the self-healing capacity of patients can be supported by artificial 
acceleration of the proliferation and differentiation of the recruited cells by applying 
growth factors and cytokines (Andreadis and Geer 2006; Varkey 2004; Vasita and 
Katti 2006). 
However, a complication caused by a burst release of high doses of growth factors 
has led to extensive ongoing studies to develop a drug delivery system that can 
provide efficacy of growth factors at lower doses, or release them gradually, or retard 
their release. Controlled delivery of growth factors can be achieved by using a 
scaffold which prevents proteolysis and loss of bioactivity, and thus enables a 
prolonged therapeutic effect (Babensee et al. 2000). 
Controlled release could lead to a more physiological healing cascade and be of 
significant importance for the tissue regeneration outcomes. For example, TGF-β 
plays a critical role in bone fracture healing through the production of ECM during the 
late phases, while SDF-1 acts in the early phases. In order to achieve improved 
healing effects, it is therefore beneficial to produce a system enabling fast release of 
SDF-1 and delayed release of TGF-beta. The delivery system should provide time- 
and dose-controlled release of the bioactive growth factor, should offer a scaffold that 
enhances cell recruitment and attachment, and should promote cell migration and 
angiogenesis. Natural growth factors from platelets deliver numerous growth factors 
in a balanced physiological ratio, and have been shown to successfully regenerate 
bone defects in clinical practice (Kitoh et al. 2004; Saluja et al. 2011; Simman et al. 
2008). However, there are some disadvantages, e.g. short retention and delivery time 
of platelets, which do not correspond with the requirements for slowly-healing 
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fractures (Saluja et al. 2011). A combination of platelets with advanced drug delivery 




5. Future perspectives 
Controlled release of proliferation and growth factors in situ is a promising 
bionanotechnological approach to tissue regeneration. Nanofibers with controlled 
release of proliferation and differentiation factors are undoubtedly a suitable tool for 
tissue engineering. The incorporation of nanofibers functionalized with bioactive 
agents, such as PRP derivatives or growth factors, into 3D composite scaffolds has a 
positive effect not only on the biomechanical properties of the scaffold, but also on 
enhancing bone or osteochondral regeneration, mainly by recruiting stem cells from 
the subchondral bone and subsequently differentiating them. In addition, the 
development of functionalized scaffolds mimicking and fitting to the bone part of the 





A promising new smart scaffold with potential for clinical use was prepared during our 
experiments. The biocompatible, biodegradable, osteoconductive and also 
osteoinductive 3D scaffold contains 0.5% type I collagen and 50% of hydroxyapatite 
with pore size around 400 um suitable for cell ingrowth and vascularization. 
Subsequently added poly-ɛ-caprolactone nanofibers improved the mechanical 
properties of the scaffold. The scaffold was enriched with mesenchymal stem cells 
and thrombocyte rich solution. The functionalized scaffold promoted new bone tissue 
formation throughout the defects, with uniform distribution of the newly-formed bone 
in vivo in a rabbit model, while the scaffold gradually degraded and was replaced by 
newly-formed bone tissue. In addition, we have found a fabrication process and 
materials which meet the European medicines agency requirements and can be 
developed for human applications. Hydroxyapatite-coated coaxial poly-ɛ-
caprolactone/polyvinylalcohol nanofibers have been developed as a promising novel 





Výsledkem in vitro a in vivo studií je nový, biokompatibilní, biodegradabilní, 
osteokonduktivní a osteoinduktivní 3D scaffold s vysokým potenciálem pro klinické 
použití. Scaffold složený z 0.5% kolagenu typu I s 50 % hydroxyapatitu s velikostí 
pórů v průměru 400 μm, je vhodný pro buněčnou migraci, proliferaci, diferenciaci a 
vaskularizaci. Následně přidaná poly-ɛ-kaprolaktonová nanovlákna zlepšila 
mechanické vlastnosti scaffoldu. Scaffold byl dále obohacen mesenchymálními 
kmenovými buňkami a trombocytárním koncentrátem jako přírodním zdrojem 
růstových faktorů. Tento funkcionalizovaný scaffold byl postupně nahrazen novou 
kostní tkání po implantaci in vivo, a to v celém objemu defektu, v kondylu femuru 
králíka za jeho postupné biodegradace. Pro výrobu tohoto scaffoldu byly navíc 
použity materiály a výrobní postupy splňující podmínky Evropské lékové agentury pro 
humánní použití. V průběhu experimentů byl též vyvinut slibný systém pro dodávání 
bioaktivních látek pro regeneraci kostní tkáně založený na koaxiálních nanovláknech 
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